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Abstract
In 1994, Chang and Moore reported on the latest of the gammaherpesviruses to infect humans,
human herpesvirus 8 (HHV-8) [1]. This novel herpesvirus has and continues to present challenges
to define its scope of involvement in human disease. In this review, aspects of HHV-8 infection are
discussed, such as, the human immune response, viral pathogenesis and transmission, viral disease
entities, and the virus's epidemiology with an emphasis on HHV-8 diagnostics.
1. The Herpesviruses
1.A. Classification of herpesviruses
More than 100 herpesviruses have been discovered, of
which all are double-stranded DNA viruses that can estab-
lish latent infections in their respective vertebrate hosts;
however, only eight regularly infect humans. The Herpes-
virinea family is subdivided into three subfamilies: the
Alpha-,  Beta-, or Gammaherpesvirinea. This classification
was created by the Herpesvirus Study Group of the Inter-
national Committee on Taxonomy of Viruses using bio-
logical properties and it does not rely upon DNA sequence
homology. However, researchers have been able to iden-
tify and appropriately characterize the viral subfamilies
using DNA sequence analysis of the DNA polymerase
gene; other investigators have been successful using the
glycoprotein B gene [2].
The Alphaherpesvirinea are defined by variable cellular host
range, shorter viral reproductive cycle, rapid growth in
culture, high cytotoxic effects, and the ability to establish
latency in sensory ganglia. In humans, these are termed
herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) and
varicella zoster virus (VZV), and represent human herpes-
viruses 1, 2, and 3 [2].
The Betaherpesvirinea  have a more restricted host range
with a longer reproductive viral cycle and slower growth
in culture. Infected cells show cytomegalia (enlargement
of the infected cells). Latency is established in secretory
glands, lymphoreticular cells, and in tissues such as the
kidneys among others. In humans, these are termed
human cytomegalovirus (HCMV or herpesvirus 5),
human herpesviruses 6A and 6B (HHV-6A and -6B), and
human herpesvirus 7 (HHV-7). HHV-7 has also been
called the roseolavirus, after the disease roseola infantum
it causes in children [2].
The Gammaherpesvirinea have a host range that is found
within organisms that are part of the Family or Order of
the natural host. In vitro replication of the viruses occurs
in lymphoblastoid cells, but some lytic infections occur in
epithelial and fibroblasts for some viral species in this
subfamily. Gammaherpesviruses are specific for either B
or T cells with latent virus found in lymphoid tissues.
Only two human Gammaherpesviruses are known,
human herpesvirus 4, referred to as Epstein-Barr virus
(EBV), and human herpesvirus 8, referred to as HHV-8 or
Kaposi's sarcoma-associated herpesvirus (KSHV) [2]. The
gammaherpesviruses subfamily contains two genera (a
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classification of closely related viruses) that includes both
the gamma-1 or Lymphocryptovirus (LCV) and the gamma-
2 or Rhadinovirus (RDV) virus genera. EBV is the only LCV
and HHV-8 is the only RDV discovered in humans. LCV is
found only in primates but RDV can be found in both pri-
mates and subprimate mammals. RDV DNAs are more
diverse across species and are found in a broader range of
mammalian species. It is thought that RDVs evolved
before LCVs [2].
HHV-8 has sequence homology and genetic structure that
is close to another RDV, Herpesvirus saimiri (HVS) [3]. HVS
can cause fulminant T-cell lymphoma in its primate host
and can immortalize infected T-cells [4]. Rhadinaviruses
can infect ungulates, mice, and rabbits and all share a par-
ticular genomic organization characterized by large flank-
ing, highly repetitive DNA repeats of high G/C content
[5].
1.B. The phenotypic structure of herpesviruses
The phenotypic architecture of the Herpesviridae  family
viruses characterizes these viruses. Customarily, herpesvi-
ruses have a central viral core that contains a linear double
stranded DNA. This DNA is in the form of a torus, exem-
plified by a hole through the middle and the DNA is
embedded in a proteinaceous spindle [6]. The capsid is
icosadeltahedral (16 surfaces) with 2-fold symmetry and
a diameter of 100–120 nm that is partially dependent
upon the thickness of the tegument. The capsid has 162
capsomeres. The three dimensional structure of the HHV-
8 capsid was determined by cryo-electron microscopy
(EM) and was found to be composed of 12 pentons, 150
hexons, and 320 triplexes arranged as expected in the ico-
sadeltahedral lattice with 20 faces; the capsids are 125 nm
in diameter [7]. Transmission EM showed a bulls-eye
appearance in the virions with electron dense cores and
amorphous teguments surrounding the viral core [8].
Interestingly, these structural characteristics were seen in
endemic KS lesions as early as 1984, but were not recog-
nized at that time as the possible etiology of the disease
[9].
The herpesvirus tegument, an amorphorous proteina-
ceous material that under EM lacks distinctive features, is
found between the capsid and the envelope; it can be
asymmetric in distribution. Thickness of the tegument is
variable dependent upon its location in the cell and varies
between different herpesviruses [10].
The herpesvirus envelope contains viral glycoprotein pro-
trusions on the surface of the virus [2]. As shown by EM
there is a trilaminar appearance [11] derived from the cel-
lular membranes [12] and contains some lipid [13]. Glyc-
oproteins protrude from the envelope and are more
numerous and shorter than those found on other viruses.
The presence of the envelope can influence the size meas-
urement of the virus under EM conditions [2].
1.C. Genomic structure and genes of herpesviruses
There are six defined DNA genomic sequence arrange-
ments for viruses in the Herpesviridae  family. Of the
human herpesviruses, EBV and HHV-8 are in class C. In
this grouping, the number of direct terminal repeats are
smaller than for other herpesviruses and there are other
repeats found within the genome itself that subdivide the
genome into unique stretches [2]. All known herpesvi-
ruses have capsid packaging signals at their termini [14].
The majority of herpes genes contain upstream promoter
and regulatory sequences, an initiation site followed by a
5' nontranslated leader sequence, the open reading frame
(Orf) itself, some 3' nontranslated sequences, and finally,
a polyadenylation signal. There are exceptions to this for-
mat because initiation from an internal in-frame methio-
nine has been reported [15].
Gene overlaps are common, whereby the promoter
sequences of antisense strand (3') genes are located in the
coding region of sense strand (5') genes; Orfs can be anti-
sense to one another. Proteins can be embedded within
larger coding sequences and yet have different functions.
Most genes are not spliced and therefore are without
introns and sequences for noncoding RNAs are present
[2].
Herpesviruses code for genes that code for proteins
involved in establishment of latency, production of DNA,
and structural proteins for viral replication, nucleic acid
packaging, viral entry, capsid envelopment, for the block-
ing or modifying host immune defenses, and transitions
from latency to lytic growth. Although all herpesviruses
establish latency, some (e.g., HSV) do not absolutely
require latent protein expression to remain in latency,
unlike others (e.g., EBV and HHV-8). Herpesviruses can
alter their environment by affecting host cell protein syn-
thesis, host cell DNA replication, immortalizing the host
cell, and the host's immune responses (e.g., blocking
apoptosis, cell surface MHC I expression, modulation of
the interferon pathway) [2].
Gene expression is occurs in two major stages: latency and
lytic growth. In the latent phase, there can be replication
of circular episomal DNA, and latency typically involves
the expression of only a few latently expressed genes. Gen-
erally, most host cells infected by herpesviruses exist in a
latent phase. When KS tissue or BCBL-1 HHV-8 infected
cultured cells are analyzed [8], the vast majority of the
infected cells are infected with latent HHV-8 virus. Only a
small percent of the cells (≤ 1%) appear to be undergoing
lytic replication in a latently infected cell line [16].Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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The herpesvirus lytic replicative phase can itself be divided
into four stages:
1. α or immediate early (IE), which requires no prior viral
protein synthesis. In the IE stage, genes involved in trans-
activating transcription from other viral genes are
expressed.
2. β or early genes (E), whose expression is independent
of viral DNA synthesis.
3. Following the E phase, γ1 or partial late genes are
expressed in concert with the beginning of viral DNA
synthesis.
4. γ2 or late genes, where viral protein expression is totally
dependent upon synthesis of viral DNA and where the
expression of virion structural genes encoding for capsid
proteins and envelope glycoproteins occurs.
1.C.a. Genomic structure and genes of HHV-8
In the viral capsid, HHV-8 DNA is linear and double
stranded, but upon infection of the host cell and release
from the viral capsid, it circularizes. Reports of the length
of the HHV-8 genome have been complicated by its
numerous, hard-to-sequence, terminal repeats. Renne et
al. [17] reported a length of 170 kilobases (Kb) but Moore
et al. [18] suggested a length of 270 Kb after analysis with
clamped homogeneous electric field (CHEF) gel electro-
phoresis. Base pair composition on average across the
HHV-8 genome is 59% G/C; however, this content can
vary in specific areas across the genome [2]. HHV-8 pos-
sesses a long unique region (LUR) at approximately 145
Kb, with at least 87 genes, flanked by terminal repeats
(TRs). Varying amounts of TR lengths have been observed
in the different virus isolates. These repeats are 801 base
pairs in length with 85% G/C content, and have putative
packaging and cleavage signals [19]. The LUR is similar to
HVS and the HHV-8 genes are named after their HVS
counterparts. New genes are still being discovered
through transcription experiments with alternative splic-
ing; the initial annotation by Russo et al. [19] was pur-
posely conservative. A "K" prefix denotes no genetic
homology to any HVS genes (K1–K15).
HHV-8 possesses approximately 26 core genes, shared
and highly conserved across the alpha-, beta-, and gam-
maherpesviruses. These genes are in seven basic gene
blocks, but the order and orientation can differ between
subfamilies. These genes include those for gene regula-
tion, nucleotide metabolism, DNA replication, and virion
maturation and structure (capsid, tegument, and enve-
lope). HHV-8, being a gammaherpesvirus, encodes more
cellular genes than other subfamily viruses. HHV-8 in par-
ticular, has a large arrangement of human host gene
homologs (at least 12) not shared by other human herpes-
viruses [19]. These genes seemed to have been acquired
from human cellular cDNA as evidenced by the lack of
introns. Some retain host function or have been modified
to be constitutively active; an example of this is the viral
cyclin-D gene [20]. Cellular homologs related to known
oncogenes have been identified in HHV-8, including
genes encoding viral Bcl-2, cyclin D, interleukin-6, G-pro-
tein-coupled receptor, and ribonucleotide reductase [19].
Other genes, such as the chemokine receptor ORF 74,
have homologues in other members of the RDV genera
[19]. A number of other genes derived from the capsid of
HHV-8 have been identified, including Orf 25, Orf 26,
and Orf 65 [19]. In addition to virion structural proteins
and genes involved in virus replication, HHV-8, typical of
a herpesvirus, has genes and regulatory components that
interact with the host immune system, presumably as an
antidote against cellular host defenses [21].
HHV-8 gene expression has been classified into three
stages by current investigators, unlike the four stages of
other herpesviruses described above [22]. Class I genes are
those that are expressed without the need for chemical
induction of the viral lytic phase. Class II genes are
induced to increased levels after chemical induction.
However, Class III genes, are only expressed after chemical
induction.
1.D. The biology of HHV-8
HHV-8 shares four main biological properties with other
herpesviruses:
1. A broad array of enzymes involved in nucleic acid
metabolism, DNA synthesis, and protein processing.
2. DNA synthesis and capsid formation occur in the
nucleus of the host cell and the viral capsid is enveloped
at the nuclear membrane.
3. Production of infectious progeny virus in the lytic phase
can kill the host cell.
4. The virus can attain a latent state in the host cell with
closed circular episomes and a minimal amount of gene
expression. Latent genomes, however, can become lytic
with the proper stimulation using chemical agents such as
sodium butyrate [2].
Several human host cells are permissive for HHV-8 infec-
tion. Two prototype cells are the B-cells of the body-cavity-
based lymphoma (BCBL) or pleural effusion lymphoma
(PEL) [23] and the spindle cells characteristic of Kaposi's
sarcoma (KS) [24]. Renne et al. [25] surveyed 38 mamma-
lian cell lines or cell types and was only able to detect by
RT-PCR the presence of infectivity from BCBL-1 derivedVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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virions in 11 of the 38. However, at least one cell type
from lymphoid, endothelial, epithelial, fibroblastoid, and
cancer cell types was permissive for infection. The 293
human kidney epithelial cell line was most susceptible in
that study [25]. Natural cellular reservoirs for HHV-8 are
CD19+ B-cells [26]. Natural infection in other cell types
have been reported for endothelium [27], monocytes
[28], prostate glandular epithelium [29], dorsal root sen-
sory ganglion cells [30], and spindle cells of KS tumors
[27].
Like other rhadinoviruses, HHV-8 might only be patho-
genic when other cofactors are involved, such as concur-
rent infection with HIV or in an immunocompromised
host. In the natural healthy host, the virus is relatively
benign [5], however, currently, there is no known host
other than humans.
1.E. Comparisons of HHV-8 to other herpesviruses
LCV (EBV) and RDV (HHV-8) genomes are more closely
related to each other than to the alpha- and betaherpesvi-
ruses [18]. HHV-8 does not immortalize B-cells in vitro, as
does EBV. HHV-8 has similar large reiterations of the TR
as found with EBV but lack EBV's long internal repeats.
HHV-8 possesses genes coding for dihydrofolate reduct-
ase (DHFR), interferon regulatory factor (IRF), G-protein
coupled receptor (GPCR), chemokine analogs, and cyclin-
D that are absent from the EBV genome [19]. Fifty-four of
75 HHV-8 genes are collinear with their EBV homologs.
Among these 54 genes, the average amino acid identity is
35%. EBV has three forms of viral latency but HHV-8 has
only one that has been identified.
1.F. Serodiagnostics of other herpesviruses
I.F.a. Alphaherpesvirinea
HSV infection is optimally detected through direct culture
of tissues or secretions with observation of cytopathic
effect (CPE) usually occurring in animal embryo cells after
1 – 3 days. Sensitivity of detection of infection is depend-
ent upon the stage of the clinical illness with an average
sensitivity of approximately 80%. The shell vial tech-
nique, a modified immunofluorescent assay, is also used.
VZV grows with more difficulty in culture and it takes 4 to
8 days until CPE is evident, but shell vial techniques can
improve the ability to detect VZV infection. Immunofluo-
rescent assay detection (IFA) using monoclonal antibod-
ies (mAb) and using samples taken from the lesions is
much quicker than culture methods. However, serology
has not been employed conventionally due to the success-
ful culturing techniques. Also, for a successful serological
diagnosis, serology requires acute and convalescent sam-
ples. Neither culture nor serology has shown optimal sen-
sitivity. Detection of specific glycolsylated proteins can
distinguish HSV-1 from HSV-2 infection [2].
I.F.b. Betaherpesvirinea
These viruses (HCMV, HHV-6 & 7) have a more restricted
host range than the alpha herpesviruses and exhibit
slower growth in culture. They are ubiquitous in the gen-
eral population but cause serious disease in immunocom-
promised patients. Diagnosis is difficult due to the
absence of clinical disease in healthy persons; virus can be
present without pathological effect in humans [2].
Current diagnosis of HCMV is complicated by the intrin-
sic labiality of the virus and that CPE is not seen in human
fibroblast culture cells until after one to three weeks of
growth. However, shell vial assays can give results in 24 –
48 hours [2]. The presence of HCMV in peripheral blood
is diagnostic for infection even if found in otherwise
healthy patients without clinical symptoms. Detection of
the HCMV protein, pp65, by an antigen assay is commer-
cially available and can be used for rapid diagnosis of
HCMV infection. The pp65 antigen comes from the
HCMV lower matrix phosphoprotein customarily found
in white blood cells. This antigen test has better sensitivity
than culture and can provide positive laboratory results in
a few hours. A mAb is used to detect pp65, but the antigen
is labile and laboratory tests need to be run within 24
hours of the blood collection [2]. HCMV IgM antibody is
diagnostic for HCMV infection in the context of mononu-
cleosis-like disease where the patient is EBV negative.
However, acute EBV infection can produce a false positive
HCMV IgM test result [31].
For HHV-6 and 7, asymptomatic viral shedding is com-
mon in the benign carrier state. Culture of these viruses
has been successful with umbilical cord lymphocytes, but
there is high background. There are a lack of diagnostic
criteria to interpret serologic test results in immunocom-
promised patients, although the finding of seroconver-
sion in infants is diagnostic [2]. The IFA test using virally
infected cells has been commonly used with success [32].
I.F.c. Gammaherpesvirinea and associated antigens
EBV replicates in vivo in lymphoid and epithelial cells and
can be cultured in immortalized umbilical cord lym-
phocytes; EBV antigen is found within the cells. Serology
is used for diagnosis of infectious mononucleosis (IM) by
detecting IgM heterophile antibodies that agglutinate
with red blood cells of horses. Serologic assays can also
measure antibodies to the EBV viral capsid antigen (VCA)
that is composed of four different proteins, the early anti-
gens (EA) of which there are five proteins, and the nuclear
antigens (NA). Testing for IgM against VCA defines acute
infection and corresponds to clinical sequelae but lasts
only a few months; however, IgG remains for the life of
the patient [33]. Anti-EA antibodies arise within a few
weeks but are not detectable in all patients with mononu-
cleosis [33]. Anti-NA antibodies arise after the advent ofVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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EA antibodies and persist for life [33]. In contrast to acute
infection, serology is not useful for post-transplant lym-
phoproliferative disorder (PTLD) and antigen detection
or detection by PCR of viral nucleic acids is required [2].
Antibody production might be compromised due to the
host's immunocompromised state or the rapid growth of
the polyclonal tumor prior to reactivation of the memory
immune response. Antigenic cross reactivity between EBV
and other human herpesviruses is rare [2]. This is demon-
strated in one study of 42 patients with nasopharyngeal
carcinoma, known to be associated with EBV and of all
persons positive for EBV VCA, only two showed reactivity
to HHV-8 lytic proteins [34].
The humoral antibody response to EBV infection is
against four serologically defined antigens [2]:
1. Epstein – Barr virus NA (EBNA) in latently infected
cells.
2. EA either in its diffuse (methanol resistant) or restricted
(methanol sensitive) compartments, expressed early in
the viral lytic cycle.
3. VCA found during the late lytic cycle.
4. Membrane antigen (MA; gp350) as part of the viral
envelope and is found on the surface of cells in the lytic
phase. Anti-MA antibody levels correlate well with neu-
tralization of the virus.
These EBV antigens are composites of several distinct pro-
teins; e.g. EBNA = EBNA 1, 2, 3A, 3B, 3C. LP and EBNA1
are the most antigenic. The detection of EBV in IM is based
upon the use of an enzyme-linked immunosorbant assay
(ELISA) to detect IgM specific to BALF2 and BMRF1, the
EA antigens, or against VCA components BFRF3 and
BLRF2; combinations of these antigens are still recom-
mended [35,36]. Diagnostics of HHV-8 will be discussed
at length in Section 8, HHV-8 Diagnostics.
2. HHV-8 Immune Responses and Infectivity
As a prelude to the discussion about HHV-8 immune
responses, antibody responses in primary EBV infection
are presented as a contrasting system. Upon the appear-
ance of clinical symptoms after EBV infection, most
patients have rising IgM antibody titers to VCA and EA;
IgA titers are transient [37]. The IgM anti-VCA response
disappears over the next few months but the IgG titer falls
to a steady state after previously peaking. In comparison,
anti-EA IgG titers fall faster and can disappear entirely [2].
Many patients show an EBNA2 IgG response during the
acute phase, but an EBNA1 IgG response usually does not
appear until convalescence [38]. This delayed EBNA1
response is probably not due to the delay in immune rec-
ognition of the latently infected cells or of the released
latent antigen because EBNA2 is recognized shortly after
infection. Possibly EBNA1 is expressed at a later time
point in the virus's life cycle. Latent membrane protein-1
(LMP-1) and LMP-2 antibody responses are rare [39].
Anti-gp350 or membrane antigen (MA) IgM antibodies
are neutralizing with the IgG response arising only much
later in the infection. These neutralizing antibody (nAb)
titers tend to reach a plateau and stay at that level for long
periods of time [37]. IgG, IgM and IgA levels are elevated
universally in the human host upon EBV infection due to
the general activation of B-cells [2]. In addition, heter-
ophile antibodies and autoantibodies, mostly of the IgM
class, show a transient increase in titer during acute
infection.
In persistent EBV infection, healthy infected individuals
are consistently anti-VCA IgG, anti-MA neutralizing anti-
body positive, and anti-EBNA1 positive. Titers can vary
greatly among individuals, but these differences are con-
sistently relative over time [2]. It is unknown why differ-
ent antibody responses exist for EBV infection.
In general, after herpesvirus infection, some patients
present with IgM levels that can be transient or at a low
level for varying periods. These can last for up to a year
making it difficult to gauge recent infection based upon
IgM reactivity alone. In addition, IgM can be detected in
viral reactivations [2]. An example of this is found with
VZV, which shows an IgM response upon reactivation
[40].
2.A. The neutralizing antibody immune response to HHV-8
Neutralizing antibodies are part of the humoral defense
system against viral infection. The presence of nAb has
been detected by searching for the effect of inhibition by
nAb against HHV-8 viral infection in transformed dermal
microvascular endothelial cells [41]. By quantifying the
level of viral infection by indirect immunofluorescence
assay (IFA), inhibition of infection was determined by
comparing the level of infection in cells obtained with
HHV-8 seropositive sera as compared to the level shown
by incubation with seronegative sera. When the seroposi-
tive sera was diluted at 1:10 or 1:50 there was significant
inhibition compared to the seronegative controls (P  =
0.036). However, at a 1:500 dilution, the inhibitory
effects of the sera disappeared. The nAb were found in the
IgG fraction as shown by depletion of IgG antibody with
protein A, which reversed the inhibitory effect.
Similarly, the presence and effect of nAb in the context of
HHV-8 infection were investigated by measuring the
infectivity in the 293 culture cell line [42]. Kimball et al.
also discovered that the nAb were found in the IgGVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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fraction and that compliment was not required for the
neutralization. Importantly, their study found that those
patients with KS had significantly lower nAb titers than
other groups, independent of their HIV status. This sug-
gested a possible role for nAb in the prevention of progres-
sion from latent asymptomatic HHV-8 infection to KS
disease. They state that the positive effects of nAb were
independent of CD4+ counts.
In contrast to these two reports, Inoue et al. observed the
effects of nAb action, but concluded that nAb do not affect
the progression to KS [43]. These antibodies were found
in both KS+ and KS- groups with prevalences of 24% and
31%, respectively, but there was no significance in the dif-
ference (P = 0.64). This conflicting finding could perhaps
be explained by the specific cohorts used. Other possibil-
ities are the use by Inoue et al. of a colorimetric reporter
system and their choice of cutoff at 30% neutralization;
where as Kimball et al. used 50% inhibition as the cut off
[42]. Additional discussion of HHV-8 antibody responses
can be found in Sections 7 and 8.
2.B. Cytologic immune responses to HHV-8
Cell mediated immunology studies of HHV-8 have indi-
cated that there are specific cytotoxic T-lymphocyte (CTL)
responses against the virus. In an investigation of five
cases of HIV negative subjects that seroconverted to HHV-
8, Wang et al. explored the CD8+ T-cell response to five
HHV-8 lytic proteins and found that CD8+ T-cells are
involved in the control of primary HHV-8 infection [44].
They found that there were no major changes in the num-
bers of T-cell phenotypes or activation of T-cells, which
differed from primary EBV infection that usually produces
global increases in the numbers of T-cells. There was also
no suppressive effect on other T-cell specificities as seen
with EBV infection. They observed distinct CD8+, HLA
class I restricted responses and increases in the interferon-
gamma (IFN-γ) response to at least three of the five lytic
antigens in each of the five subjects. No antigen was dom-
inant in the elicited T-cell response. They observed that
HHV-8 antibody titers to lytic IFA proteins paralleled the
cytolytic responses. The CD8+ reactivity declined after sev-
eral years possibly because of the lack of stimulation; the
normal biology of HHV-8 is to enter a more latent state
after primary infection. More T-cells produced a response
of INF-γ production as opposed to CTL precursor produc-
tion, but neither response was as strong as that observed
when the T-cells were challenged with the HCMV pp65
antigenic protein. Osman et al. investigated HLA class I
restricted CTL activity directed against the HHV-8 K8.1
lytic antigen [45]. They also investigated an additional
lytic protein (K1) and one latent protein (K12) as anti-
gens. Chromium release assays showed that CTL reactivity
was detected against all three proteins, but not every
patient had reactivity to all three antigens. Specific HLA
alleles were able to present more than one of the viral pro-
teins; e.g., HLA B8 could present all three antigens. Most
patients with KS and were HIV+ did not have CTL
responses indicative of compromised cellular immune
systems. In one patient, whose KS had resolved under
HAART therapy, CTL activity was restored. In general,
these investigators showed that higher titers against HHV-
8 LANA1 (Orf 73), i.e., more severe KS, correlated with
less CTL response.
In a study of seroconversions in Amsterdam, Goudsmit et
al. found that CD4+ T-cell levels did not affect the rate of
seroconversions, but once HHV-8 infection had occurred,
a decline in CD4+ cells was associated with increasing
reactivity against the Orf 65 antigen [46]. Similar findings
have been reported by Kimball et al. where persons with
KS have higher levels of anti-HHV-8 antibodies and lower
CD4+ counts than those without KS, but where both pop-
ulations have HIV infection [42]. This suggests that viral
replication had increased in the context of a more limited
CD4 response. Recent investigation [47] has shown that
NK cell function is important for the control of latent
HHV-8 infection and abrogation of this important
immune response can lead to more progressive KS
disease.
2.C. Reactivation of HHV-8 infectivity
Using peripheral blood mononuclear cells (PBMCs)
culled from KS patients and grown in culture, Monini et
al. showed that reactivation of HHV-8 required at least the
inflammatory cytokine (IC) INF-γ [48]. They observed
that both B-cells and monocytes latently infected with
HHV-8 responded to this IC with induction of lytic repli-
cation. They proposed that increases in HHV-8 viral load
are due to the reactivation of the virus after exposure to
INF-γ. They also proposed that a likely scenario of KS
pathogenesis is the recruitment of circulating monocytes
into peripheral skin tissues, where upon exposure to ICs,
their latent HHV-8 genomes enter into the lytic phase. The
monocytes then rupture and free virus is available to
infect local tissues. The monocytes might also differenti-
ate into macrophages or spindle cells after exposure to the
ICs and form the basis of latent HHV-8 infection in the
tissues.
Reactivation is possible in the context of autologous
peripheral blood stem cell transplantation. Luppi et al.
[49] presented a case report that showed HHV-8 viral load
in the serum of the transplant patient concomitant with
fever, rash, diarrhea, and hepatitis some 17 days after the
transplant. The patient had lytic antibodies before and
after the transplant indicating a reactivation event.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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2.D. Corporeal sites of HHV-8 infection
A number of studies [49-56] have investigated by molecu-
lar methods the presence of HHV-8 virions, as evidenced
by the presence of viral DNA in body fluids and tissues of
several at-risk populations (Table 1). PBMCs were the
most commonly studied sample site, but a number of oth-
ers, including serum or plasma, semen, saliva, and stool
have been investigated (Table 1). PCR sensitivities were
below 100 copies, although some studies used nested PCR
[52] or Southern blotting [50].
At least four investigators used the K330 PCR as originally
developed by Chang et al. [1]. Five articles described test-
ing KS patients [50-52,54,55] and another five [50-
52,55,56] compared HIV+ and HIV- subjects for the pres-
ence of HHV-8. Grandadam et al. [53] investigated multi-
centric Castleman's disease (MCD) in HIV+ patients and
Luppi et al. [49] followed the unique case of a viral reacti-
vation. For persons with KS, significant differences were
found between sample sites; the HHV-8 prevalence was
higher in KS lesions over that found in peripheral blood
mononuclear cells (PBMCs), which were about equal in
prevalence to saliva (Table 1). These three sites were better
for finding the presence of HHV-8 rather than using
plasma (P <10-6; P = 0.054; P ≤ 0.02, respectively). For
HIV+ persons, saliva and PBMCs were equivalent (P =
0.539) but both had a significant greater frequency of pos-
itive samples than were found in plasma (P = 0.016 and P
= 0.031, respectively). Analysis of HIV- persons showed
that saliva contained significantly more viral sequences
than either PBMCs or plasma (P = 0.001 and P = 0.0006,
respectively), which were commensurate with each other
(P = 0.476).
It is noteworthy to add that several authors have observed
the detectable presence of HHV-8 DNA to be intermittent
[49,51,57,58]. Perhaps this has contributed to the overall
lack of sensitivity of PCR in detecting HHV-8 infection. In
keeping with this observation, Simpson et al. [59] stated,
"...KSHV genomes were detected in peripheral blood
monocyte DNA from KS patients less frequently than anti-
bodies to either KSHV antigen in serum". Smith et al. [60]
added that, "Overall, our serologic assay appeared more
sensitive than PCR analysis of PBMC for the detection of
HHV-8 infection". This last statement was reiterated by
other authors (e.g. Angeloni et al. [61], Campbell et al.
[62]). HHV-8 viremia is described at more length in Sec-
tion 8, HHV-8 Diagnostics.
3. Pathogenic Mechanisms of HHV-8
The diversity of the HHV-8 genes allows the virus to
assault and modulate its human host with many strate-
gies. These pathogenic effects can promote active changes
in the infected human host, such as to increase cytokine
production or to suppress MHC Class I (MHC I) presenta-
tion of viral proteins to the immune system. The patho-
genic activities that are due to HHV-8's unique K-series
genes are summarized.
Interleukin-6 (IL-6) is a B-cell growth factor and its altered
expression has been linked to several human diseases and
malignancies, including MCD with its characteristic plas-
macytosis and hypergammaglobulinemia. HHV-8 viral
cytokine vIL-6 is encoded by the unique K2 gene, which
exhibits 25% amino acid identity with the human homo-
logue [63]. This viral gene is unique to HHV-8 among the
other gammaherpesviruses and is the only HHV-8
encoded cytokine. It is a Class II transcript in that it is con-
stitutively expressed in the BCP-1 cell line, but its expres-
sion is greatly increased after induction with TPA; it is a
Class III transcript in the BC-1 cell line [63]. This feature
of the protein implies that its pathogenic effects can be in
the context of active viral infection. vIL-6 had activity on
human myeloma cells [64], where exogenous application
induced DNA synthesis and proliferation in the INA-6
myeloma cell line; this cell line is strictly dependent upon
exogenous IL-6 for growth. Expression of vIL-6 mRNA
transcripts was detected by in situ hybridization in tissue
samples of KS, PEL, and MCD disease patients [65], dem-
onstrating the in vivo expression of this cytokine. Staskus
et al. showed that vIL-6 might be important in the patho-
genesis of these three HHV-8 associated disorders, but the
viral cytokine is variably expressed in the HHV-8 infected
cells of these diseases [65]. For example, the number of
vIL-6 copies in KS, PEL, and MCD cells was 10–100, 100–
1000, and >1000 copies, respectively, per cell. Low levels
of vIL-6 have also been observed in KS lesions by immu-
nohistochemistry [63,66].
Table 1: Compilation of select studies investigating the molecular presence of HHV-8 in different tissues and body fluids. KS, HIV+, and 
HIV- represent three populations at high, medium, and lower risk of HHV-8 infection, respectively.
KS Lesion Normal 
Skin
PBMC Plasma or 
Sera
Semen Saliva Feces Other
KS+ 63/70 (90%) 17/57 (30%) 94/188 (50%) 33/151 (22%) 7/60 (12%) 26/71 (37%) 0/29
HIV+ 0/10 22/268 (8.2%) 5/164 (3.0%) 4/57 (7%) 9/87 (10%) 10/228 (4.4)
HIV- 0/1 3/381 (0.8%) 0/218 3/168 (1.8%) 7/108 (6.5%) 10/332(3.0)Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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Several HHV-8 K-genes are active in modulating the adap-
tive immune response to HHV-8 infection. The K3 and K5
genes allow HHV-8 to evade detection by removing MHC
I from the cell surface [21]. The proteins encoded by K3
and K5, MIR-1 and MIR-2, respectively, use a unique
mechanism of enhanced endocytosis of the MHC I mole-
cules and their subsequent degradation in lysosomes.
MIR-2 protein also down regulates ICAM-1 and B7.2,
accessory proteins necessary for proper T-cell stimulation
[67].
The lack of MHC I on the cell surface can signal increased
natural killer (NK) cell activity, but NK cells are modu-
lated by the K13 gene product, v-FLICE inhibitory protein
(vFLIP) [68]. Despite the Fas-dependent signaling (apop-
tosis triggering) caused by the NK cells, apoptosis is
impaired because vFLIP binds to cellular procaspase-8
preventing its proteolytic cleavage into apoptotically
active forms.
Another tactic to alter the cell-mediated response to HHV-
8 infection is to make sure this response does not occur
upon infection. HHV-8 creates a microenvironment
where by there is preferential recruitment of T cell type 2
(Th2) lymphocytes with the release of IL-4 and IL-5
cytokines, which polarizes the immune response towards
an antibody predominant immune reaction [69]. It is the
Th1 response with the characteristic release of Inf-γ that
stimulates cell-mediated immunity. Three HHV-8 chem-
okines, vCCL1, vCCL2, and vCCL3, also referred to as
vMIP-1, vMIP-II, and vMIP-III, respectively, are encoded
by the K6, K4, and K4.1 Orfs, respectively [70]. These
chemokines activate Th2 responses through the CCR8,
CCR3, and CCR4 receptors [70], respectively, but are
antagonistic for the receptors that result in chemotaxis of
Th1 and NK lymphocytes [71]. The vCCL3 is found in KS
tumors and is thought to contribute to its pathogenesis
[72]. Another HHV-8 gene, K14, encodes a neural cell
adhesion-like protein (OX-2) that also promotes Th2
polarization and the production of inflammatory
cytokines, such as IL-6 [73]. Other unique K-genes modify
the immune system by interacting with the µ-chains of B-
cell receptors and blocking transport to the cell surface
(K1 or KIS) or by inhibiting interferon signaling (K9 or
vIRF-1) [70]. The diverse repertoire of immune suppres-
sive strategies exhibited by HHV-8 could explain the
virus's success in establishing a high prevalence in popu-
lations where it is being actively transmitted, such as sub-
Saharan Africa. However, it then brings into question why
HHV-8 is not more successful in establishing infection in
developed counties, even with people whose immune sys-
tems are compromised or constantly stimulated.
4. Transmission of HHV-8
Patterns of transmission for HHV-8 are being better
defined as our understanding of the pathogenesis of this
virus increases and testing methods are used strategically.
The virus, first thought to be transmitted only sexually, is
now also considered transmissible through low risk or
more casual behaviors.
4.A. Sexual Transmission
The transmission of HHV-8 through sexual activities has
been documented [74]; men with homosexual behaviors
showed a 38% prevalence of HHV-8 as compared to 0%
of men with no such activity. The increased prevalence
correlated with the presence of sexually transmitted dis-
eases (STD) and the number of male sexual partners. The
presence of both HIV and HHV-8 produced a 10-year
probability of 50% for developing KS [74].
Transmission from male genital secretions, specifically
semen, is unlikely due to the low prevalence of detectable
HHV-8 in semen samples obtained from both HIV+ or
HIV- persons [52,55,56]. In a study of women with KS
from Zimbabwe, between 28% and 37% had detectable
HHV-8 DNA in their vaginal or cervical samples [75], but
HHV-8 DNA was not found in any of the women without
KS, even those with HHV-8 seropositivity. A possible
explanation why perinatal transmission is infrequent in
prevalence studies might be that transmission is limited to
immunocompromised mothers where titers might be
higher [75].
HHV-8 DNA is found most frequently and with increased
viral burdens in saliva or other oral samples [56]. Sexual
practices that include oral sex could therefore increase the
possibility of transmission. Persons having STDs, such as
syphilis and HIV, have an increased risk for greater HHV-
8 prevalence [76]. However, in a study of 1,295 women in
four USA cities, Cannon et al. did not find an association
between the number of sex partners or engagement in
commercial sexual practices to be a risk for increased
HHV-8 prevalence [76].
4.B. Blood-borne transmission
Identification of HHV-8 in blood donors [58,77] has
raised concern about the safety of the blood supply. Other
reports [78] have tempered the concern of blood borne
transmission after observing no transmission in 18 recip-
ients of HHV-8 seropositive blood components. However,
because of the small sample size, additional studies are
required for this low prevalence population. In a multi-
center study of 1,000 blood donors, approximately 3% of
blood donors were considered seropositive, but none of
the 138 total seropositive samples had detectable HHV-8
DNA in their PBMCs [79]. Without detectable virus, the
possibility of infectious transmission seems remote.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
Page 9 of 32
(page number not for citation purposes)
However, blood-borne transmission seems to occur, but
rarely. Two epidemiological markers for blood borne viral
infection, HCV positivity and daily-injected drug use,
were associated with increased HHV-8 infection in four
large groups of women in the USA [76]. However, the
overall prevalence of HBV and HCV among irregular drug
users was higher than found with HHV-8, indicating a
lower relative frequency of transmission of this
herpesvirus.
Evidence that HHV-8 can be transmitted in populations of
intravenous drug users (IVDU) and those HCV+, shows
that transmission via blood is possible, albeit with diffi-
culty [80]. Larger studies are required to determine if
HHV-8 is a true threat to the blood supply. Such studies
will be difficult to conduct due to the difficulty in detect-
ing infectious virus in healthy individuals, the lack of cul-
ture methods to tests for cytopathic effect, and the
anonymous nature of blood donations, which does not
allow for follow up testing.
Important risk factors for transmission of the virus are a
spouse's seropositivity and maternal seropositivity [81].
Although spousal seropositivity could include sexual
transmission, transmission to children precludes this
route, indicating more casual transmission is possible.
Horizontal asexual transmission within families has been
observed by other investigators [82]. Vertical transmission
from mother to child at or before birth is also infrequent
with few children from HHV-8 infected mothers showing
HHV-8 sequences in their PBMCs at birth [83,84]. In a
study of the presence of HHV-8 DNA in matched pairs of
breast milk and saliva from the same mother, no HHV-8
sequences were found in the breast milk, but 29% of the
saliva samples had HHV-8 DNA; therefore nursing of
infants appears unlikely to be a route of infection [85],
although, another study seemed to contradict this finding
[86].
Of all anatomic sites, HHV-8 DNA is found most fre-
quently in saliva, which also has higher viral concentra-
tions than other secretions [56]. For this reason, it has
been hypothesized that saliva could be the route of casual
transfer of infectious virus among family members. It has
been hypothesized that customarily licking an insect bite,
such as from a mosquito, could transfer the virus [87].
4.C. Transplants
4.C.a. Organ
Transmission of other herpesviruses (e.g., HCMV and
HHV-6) has been documented [88] and the body of evi-
dence is growing that HHV-8 disease after organ trans-
plantation is a concern for the transplant physician. Most
reports in the literature have presented data describing the
prevalence and the possible ramifications of HHV-8 infec-
tion on donor kidney recipients.
However, the concern of HHV-8 transmission in the con-
text of organ transplantation has two problems. First,
there are no large studies of the donor's and the recipient's
HHV-8 serostatus and presence of HHV-8 in donor blood
and organ. Properly done, both antibody prevalence and
a determination of infectious virus by PCR would be nec-
essary. Follow up measuring possible seroreactivity every
few months after transplant would be critical. Second,
even once the problem is defined, there are no current
establish procedures or parameters to monitor the
patients both diagnostically and clinically; seemingly,
both problems would have to be addressed in tandem.
In areas where endemic KS is not found and in normally
healthy people, HHV-8 infection has not been shown to
be a life threatening infection. However, in the context of
immunosuppression, as with organ transplants, both pri-
mary infection and reactivation become a proven concern.
Post-transplant immunosuppression can cause iatrogenic
KS to appear [89]. The clinical significance of post-trans-
plant KS can be rejection of the graft and death of the
patient. In a study of 356 post-transplant patients with KS,
40% had visceral involvement, a manifestation of KS with
poor prognosis, and 17% of those with visceral KS died
from the tumor [89]. The KS tumor can recede after with-
drawal of immunosuppressive therapy, but with immu-
nological recovery, graft loss or organ impairment often
emerges as a unwanted condition [89]. In an early study,
Parravicini et al. [90] suggest that post-transplant KS is
caused by emergence of latent HHV-8 after previously
infected but clinically well transplant patients are immu-
nosuppressed. Immunosuppression, such that occurs in
transplant recipients, is known to facilitate reactivation of
herpesviruses, (e.g., disseminated herpes zoster) and is
associated with an increased incidence of herpesvirus
associated lymphoproliferative malignancies [91].
Of importance, seroprevalence to HHV-8 increased from
6.4% to 17.7% overall one year after renal transplanta-
tion. In addition, seroconversion to HHV-8 occurred
within the first year after renal transplantation in 25 of
220 patients and KS developed in two of the 25 within 26
months after transplantation [92]. KS developed within
20 months in two renal transplant recipients from the
same cadaveric donor; Orf 73 genotyping confirmed that
the virus was transmitted from the donor [93]. Detection
of HHV-8 in the allograft kidneys or increases in antibody
titer can be prognostic indicators of increased risk for KS
[94]. Other studies have found the median time to KS
from transplantation to be between 7 months [90] and 24
months [95].Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
Page 10 of 32
(page number not for citation purposes)
In another study, the increased risk of acquiring HHV-8
infection was shown by 10% of 100 transplant patients
who seroconverted to HHV-8, however, there was no pat-
tern associated with the type of organ donated, and none
of the donors that could be tested were seropositive [96].
Therefore the investigators concluded that the infection
came from sources other than the transplanted organ;
however this conclusion is lacking because healthy
infected individuals (i.e., healthy organ donors) in the
USA are less likely to exhibit antibodies, similar to blood
donors, however, the organ might still harbor infectious
virus or KS precursor cells [93,94].
In a comparison of kidney and liver transplants, serocon-
version was observed in 12% of transplant patients, com-
bined. The incidence of KS in kidney patients was higher
than in liver recipients [97]. Importantly, patients already
infected with HHV-8 had a greater chance to develop KS
from viral reactivation than from primary infections [97].
In a large study of solid organ transplant recipients in
Spain (n = 1,328), Munoz et al. [95] reported that the
overall KS incidence was 1 in 200 with more males diag-
nosed with KS than females (6:1 ratio). High HHV-8 anti-
body titers or seroconversions were prognostic indicators
of possible KS development.
Because increased prevalence in transplant patients might
be due to reactivation of HHV-8 and the subsequent
increase of antibody tiers [98], molecular methods,
although normally less sensitive, would be better indica-
tors of transmission. Another possibility would be the use
of antibody avidity assays to detect highly avid antibodies
that would be indicative of reactivation events [99].
Post-transplant KS can develop in the recipient from
transmission of the virus from the donor to the recipient
[93,94], and from KS progenitor cells seeded along with
the donor organ, which undergo neoplastic change, and
progress into KS [100]. HHV-8 DNA can be detected in the
KS lesions from patients suffering from post-transplant
cutaneous and visceral KS. Other organs without evidence
of KS involvement can test positive for HHV-8 sequences
[101], as can circulating spindle cells infected with HHV-
8 [102]. Disease entities associated with HHV-8 in the
context of transplantation continue to be discovered. In at
least one report, investigators have suggested that EBV-
negative post-transplant lymphoproliferative disorders
(PTLD) might be caused by HHV-8 [103].
4.C.b. Bone marrow/Peripheral blood stem cell
Non-neoplastic disease associated with HHV-8 has been
documented [49,104]. Bone marrow failure was observed
after a kidney transplant and after an autologous periph-
eral blood stem cell (PBSC) transplant for non-Hodgkin's
lymphoma (NHL). HHV-8 produced a syndrome of fever,
marrow aplasia and plasmacytosis; these occurred after
primary infection and reactivation, respectively [104].
Neither patient presented with KS, but both had detecta-
ble HHV-8 sequences by PCR after transplantation and at
the presentation of symptoms – both patients died.
Another case report [49] showed reactivation of HHV-8 in
a seropositive patient and documented nonmalignant dis-
ease 17 days after PBSC transplantation in the context of
NHL. The patient presented with fever, cutaneous rash,
diarrhea, and hepatitis; here too HHV-8 DNA was
detected in the serum by PCR with higher viral loads with
exacerbation of symptoms. Therefore, transplant patients
who are HHV-8 positive could benefit from close clinical
follow-up to preempt the occurrence of KS with judicious
use of immune suppressive therapy or antiviral drugs, or
to begin the early and therefore more effective treatment
of the tumor once detected.
5. Diseases of HHV-8
HHV-8 poses challenging questions of diagnosis and
pathology related to its role in the etiology of several
human malignancies including KS, MCD, PEL, and possi-
bly multiple myeloma (MM) and sarcoidosis, among
others.
5.A. Primary infection
Identification of HHV-8 primary infection has been diffi-
cult due to the low incidence of infection in most popula-
tions studied, and because of the lack of known defining
features. By using a diagnosis of exclusion and the tempo-
ral occurrence of symptoms and diagnostic criteria, lim-
ited studies have suggested several defining clinical
sequelae of HHV-8 primary infection. In 15-year longitu-
dinal study of >100 HIV negative men to study the natural
history of primary HHV-8 infection, five cases of HHV-8
seroconversion were identified [44]. The effects of HHV-8
primary infection were explored in the absence of HIV
coinfection and no debilitating disease was observed in
the five seroconverters. Four patients exhibited clinical
symptoms, which ranged from mild lymphadenopathy
and diarrhea to fatigue and localized rash. These symp-
toms were significantly associated with HHV-8 serocon-
version when compared to the 102 seronegative subjects
who remained well.
Organ transplantation is another clinical setting for pri-
mary infection. In a patient receiving a renal transplant,
bone marrow failure was associated with a syndrome of
fever, marrow aplasia, and plasmacytosis [104]. The
patient did not present with KS, but HHV-8 sequences
were detected by PCR after transplantation and at the
presentation of symptoms; the patient did not survive.
This limited experience suggests that in the context of
immunosuppression, primary infection can be lethal, butVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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in healthy individuals, the infection presents with flu-like
symptoms.
5.B. Kaposi's sarcoma
KS was first described by Moritz Kaposi in the 1870s [105]
and was described as an aggressive tumor affecting
patients younger than those currently observed. For all
epidemiological forms of KS, the tumor presents as highly
vascularized neoplasm that can be polyclonal, oligo-
clonal, or monoclonal. It's antigenic profile suggests
either endothelial, lympho-endothelial, or macrophage
origins [106]. Although the four epidemiological forms of
KS have different clinical parameters, such as anatomic
involvement and aggressiveness of the clinical course,
they have HHV-8 infection in common with indistin-
guishable histopathology [107]. It is therefore believed
that this transforming virus is the causative agent of KS
and that HHV-8 fulfills Hill's criteria for causing KS
[108,109].
HIV infection substantially increases the risk for develop-
ment of KS, and therefore, the incidence of KS has
increased substantially during the HIV pandemic, particu-
larly in younger HIV-infected patients [110]. Striking dif-
ferences in risk for acquiring AIDS-KS exist between
different HIV transmission groups, varying from a high of
21% for homosexual men to a low of 1% for men with
hemophilia. Women who acquired HIV infection by het-
erosexual contact with bisexual men were also at an
increased risk for developing AIDS-KS [110]. Although the
incidence of KS has decreased recently with the advent of
highly active anti-retroviral (HAART) therapy, the appear-
ance of drug resistant strains of HIV raises concern for a re-
emergence of KS cases.
Browning et al., using a cell culture detection method,
observed that the characteristic spindle cells of KS are
present in the peripheral blood of patients presenting
with KS; more importantly, these cells were found in the
blood of HIV+ homosexual men, who are at higher risk
for developing KS, than HIV+ IVDUs [102].
The first strong evidence that human herpes virus 8 (HHV-
8) was the etiological agent of KS came from the use of a
novel molecular technique, representational difference
analysis (RDA) [1]. This complex molecular method iden-
tified viral molecular sequences in KS tumor tissue that
were not present in paired normal tissue from the same
individual [1]. The presence of nucleic acid sequences of
the virus in tissues from all forms of KS [111] throughout
the world, and the demonstration of antibodies to HHV-
8 in KS patients from a number of serologic studies [112]
has supported the association of this virus with KS.
Because of its prominent association with KS, the virus is
often referred to as Kaposi's sarcoma-associated herpesvi-
rus or KSHV.
Proof of HHV-8's etiology in KS comes from the detection
of HHV-8 nucleic acids in KS tissues but not in healthy tis-
sues, from sero-epidemiological and molecular studies
showing correlations to the risk of developing KS and pro-
gression of KS disease. The detection of antibodies to lytic
HHV-8 antigens can be used as a predictor of develop-
ment of KS [113]. Prospective studies of persons who sub-
sequently developed KS, documented the appearance of
infection more than 24 months prior to tumor develop-
ment [114]. Data have shown that infection of primary
endothelial cells with HHV-8 causes long term prolifera-
tion and transformation [115]. HHV-8 is detectable in the
spindle cells of all forms of KS and in the nearby in situ
endothelial cells [27].
5.B.a. Classic KS
The classical or sporadic form of KS (CKS) is an indolent
tumor affecting the elderly, preferentially men, in Medi-
terranean countries such as Italy, Israel, and Turkey [116].
The lesions tend to be found in the lower extremities and
the disease, due to its non-aggressive course, usually does
not kill those afflicted. HIV infection, unlike HHV-8, is
not typically associated with CKS [117].
The older the age of the patient, the greater the risk of CKS
disease progression; dissemination of KS lesions is more
likely if immunosuppression also exists [118]. Certain
behaviors, such as corticosteroid use and infrequent bath-
ing were found to be risk factors for greater incidence of
CKS but surprisingly, increased cigarette smoking actually
lowered the risk [119]. The increased prevalence in Sar-
dina of HHV-8 and CKS among family members of KS
patients indicates that transmission of HHV-8 is probably
by asexual routes [61].
5.B.b. AIDS-KS
In the context of the acquired immunodeficiency syn-
drome (AIDS), KS is the most common malignancy and is
an AIDS defining illness [120]. AIDS-KS is a more aggres-
sive tumor than CKS and can disseminate into the viscera
with a greater likelihood of death [121]. Unlike CKS, it
presents more often multifocally and more frequently on
the upper body and head regions [117].
In those with HIV infection, HHV-8 prevalence increases
with higher risk of KS, and in patients with HHV-8 sero-
conversion there is a greater likelihood of KS development
[74]. KS was more likely to develop when HHV-8 serocon-
version occurred after the patient already had HIV
[122,123]. An increased slope of CD4+ cell decline and
higher HIV viral loads also suggested increased chances of
KS development [122].Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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However, HIV infection alone might not be enough to
increase the risk of KS. In a study of Ethiopians who had
immigrated to Israel, only 0.85% of them with AIDS
developed KS, as compared with 12.5% of non-Ethiopian
AIDS patients (P < 0.001). The low risk of KS exists in the
face of high HHV-8 prevalence (above 39%) in HIV+ and
HIV- Ethiopian populations [124]. Clearly, other factors
are necessary for KS development and ethnic or genetic
protective factors might be involved.
5.B.c. Endemic KS
HHV-8 was prevalent in Africa prior to the HIV epidemic,
and therefore, was responsible for the large prevalence of
KS seen on the continent before HIV changed the scope of
KS presentations [125]. Prior to HIV coinfections,
endemic KS affected men with an average age of 35 and
very young children [126]. In Africa, endemic KS is found
more often in women and children than in other areas of
the world [125]. It presents in four clinical forms with one
form similar to CKS, but found in younger adults; the
other three forms are more aggressive, similar to AIDS-KS
[117]. They vary in the age of presentation and the sites of
involvement.
HIV coinfection has raised the prevalence of KS signifi-
cantly in Africa. In Uganda, for example, prior to 1970, KS
was diagnosed in no more than 7% of the male cancer
population and in none of the female cancer population.
However, by 1991, KS prevalence had risen to 49% in
male cancer patients and to 18% in females [126]. The KS
prevalence has increased in Africa, even in HIV negative
populations, for unknown reasons [125].
Despite different clinical KS presentations, all forms of KS
are associated with HHV-8 infection [111,127]. Parallel-
ing the endemic KS pattern in children, HHV-8 infection
in children is also high with seroprevalence reaching adult
levels by the age of 20 and in certain locations even earlier
[128]. This occurrence of horizontal infection in the
young is similar to that seen with EBV in other continents
[128]. Despite equal prevalences of HHV-8 in HIV-1 and
HIV-2 patients, KS is found almost exclusively in persons
infected with HIV-1 [129].
5.B.d. Iatrogenic KS
More extensive information on transplant-associated KS
and the involvement of HHV-8 can be found in the Liter-
ature Review: Section 4, Transmission of HHV-8. Briefly,
iatrogenic KS can present either as a chronic condition or
with a more rapid course [117]. Immunosuppression,
such that occurs in transplant recipients, is known to facil-
itate reactivation of herpesviruses [91] and so too with
HHV-8, transplant patients under immunosuppressive
therapy can present with KS. Withdrawal of the therapy
can cause the KS to regress [117].
Iatrogenic KS seems to vary in its geographic prevalences,
perhaps reflecting the varying HHV-8 prevalence in the
general populations of different countries [125]. KS
appears most frequently in renal transplant patients [116]
and in conjunction with cyclosporine treatment, used fre-
quently in kidney transplant patients as an immunosup-
pressive drug; this steroid has been shown to reactivate
HHV-8 in vitro [130].
5.C. Primary effusion lymphoma
First identified as a subset of body-cavity-based lympho-
mas (BCBL), PELs contain HHV-8 DNA sequences [23].
These lymphomas are distinct from malignancies that
cause other body cavity effusions. PELs are characterized
by several pathological features: 1) They do not exhibit
Burkitt lymphoma-like morphology and do not have c-
myc gene rearrangements; 2) They have a distinctive mor-
phology comparable to large-cell immunoblastic lym-
phoma and anaplastic large-cell lymphoma; 3) They occur
frequently in men; 4) They present initially as a lympho-
matous effusion and remain localized to the body cavity
of origin; 5) They express CD45 with frequent absence of
B-cell associated antigens; 6) They exhibit clonal immu-
noglobulin gene rearrangements; 7) They can contain
Epstein-Barr virus; 8) They lack oncogene rearrangements
in genes such as bcl-2 and p53. Finally, patients with PELs,
especially in the context of AIDS, invariably are infected
with HHV-8 [23,131]. PEL cell lines have 50–150 copies
of HHV-8 episomes per cell [8,132-136].
Divining the association of PELs with HHV-8's etiology
has been difficult, because most PELs occur in the context
of HIV infection, and the PELs account for only 0.13% of
all AIDS malignancies in AIDS patients in the USA [137].
Importantly, PELs occur with an increased frequency in
patients with prior KS [125]. In non-AIDS patients, the
disease has been termed "classic" PEL by Ascoli et al. [138]
where it presents in HIV negative patients, but with simi-
lar risk factors as CKS.
5.D. Multicentric Castleman's disease
HHV-8 has been found variably in association with MCD.
MCD is a rare polyclonal B-cell angiolymphoproliferative
disorder for which vascular proliferation has been found
in germinal centers. It presents in heterogeneous forms
both clinically and morphologically [139]. However,
most of the B-cells in the tumor are not infected with
HHV-8, and the HHV-8 infected cells are primarily located
in the mantel zone of the follicle [140]. It is thought that
uninfected cells are recruited into the tumor through
HHV-8 paracrine mechanisms, such as vIL-6 [66], a
known growth factor for the tumor. More than 90% of
AIDS patients with MCD are HHV-8 positive, whereas
MCD in the context of no HIV infection has a HHV-8
prevalence of approximately 40% [141]. Because of itVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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rarity, MCD is difficult to closely associate statistically
with HHV-8.
5.E. Other diseases
5.E.a. Sarcoidosis
Sarcoidosis is a multisystemic granulomatous disease of
unknown etiology that can involve many different organs
such as the lungs, lymph nodes, and skin. Currently, a
diagnosis can be established when clinical and radiologi-
cal findings are confirmed by histological tests showing
noncaseous granulomas in more than one tissue [142].
Di Alberti et al. reported that HHV-8 DNA was signifi-
cantly more prevalent in pulmonary tissues, lymph nodes,
skin and oral tissues in 17 Italian patients with sarcoidosis
than in tissues from 96 control specimens [143]. How-
ever, a study by Belec et al. did not detect HHV-8
sequences in sarcoid tissues from French patients with sys-
temic sarcoidosis [144]. Very little diagnostic HHV-8
serology has been reported on sarcoid patients. In one
report, 18% of patients were seropositive, but the investi-
gators concluded that this was not different from the
observed prevalences in the patients' respective geo-
graphic regions [145].
5.E.b. Multiple myeloma
There is debate concerning the etiology of MM. MM is the
most common lymphoid cancer found in Blacks and the
second most common in Caucasians [146]. It is a B cell
malignancy of clonal origin in which the cancer cells, con-
sidered to be plasma cells, secrete monotypic immu-
noglobin. The pathogenesis of MM has been thought to
include an initial antigenic stimulus of B cells followed by
further mutagenic events. Studies have shown that auto-
crine and paracrine loops involving cytokines such as IL-6
[147], TNF, and IL-1β [148] are important as stimuli for
growth of the MM cells. It has been believed that T cells
and the bone marrow stroma are the sources of these
cytokines. Three oncogenes have been implicated in MM;
ras, c-myc, and p53 with prevalences of 30%, 25%, and
15–45%, respectively [146].
The possible role of HHV-8 in MM has been debated and
a full report of the evidence is beyond the scope of this
review. In brief, Rettig et al. [149] who originally reported
that there was an association between the virus and the
disease, investigated 15 MM patients along with eight
patients presenting with monoclonal gammopathy of
unknown significance (MGUS). They used PCR to amplify
the KS330233  sequence of HHV-8 from bone marrow
(BM) mononuclear and stromal cells of the MM patients.
Southern blotting of the PCR fragments using an internal
fragment confirmed the PCR results. They were able to
amplify HHV-8 sequences from cultured BM stromal cells
from 15/15 MM patients. However, none of the 23 non-
cultured BM mononuclear preparations amplified. Said et
al. [150] supported Rettig et al.'s claim that MM and HHV-
8 were closely associated by finding 17 out of 20 BM biop-
sies from MM patients exhibiting HHV-8 positive cells.
Gao et al. [151], provided important supportive serologi-
cal evidence; of 27 MM patients, 81% and 52% possessed
lytic and latent antibodies, respectively. All eleven
patients with progressive MM were HHV-8 positive. The
increased presence of lytic antibodies as opposed to latent
antibodies was indicative of past or currently active viral
infection in the MM patients.
Contrary to these findings, other groups have found a lack
of supporting evidence. Whitby et al. [152] found latent
antibodies in only 4/37 MM and in only 2/36 MGUS
patients, but these prevalences were not significantly dif-
ferent from patients with Hodgkin's lymphoma, NHL, or
normal blood donors. Additionally, whereas Rettig et al.
postulated that MGUS might be the precursor of MM
through infection with HHV-8 [149], Whitby and col-
leagues found that 4 persons with MGUS who developed
MM were HHV-8 negative, in contrast to two patients with
antibodies to HHV-8 who had not exhibited MM symp-
toms after 36 and 48 months. MacKenzie et al. [153] and
Parravicini et al. [154] found only 2/78 and 1/20 MM
patients to be seropositive to latent antigen, respectively.
The presence of lytic antibodies in MM patients has also
been difficult to find by other investigators. Utilizing
recombinant ORF 65 antigen in ELISA and Western blot
formats, MacKenzie et al. [153] and Parravicini et al. [154]
found lytic antibodies in only 2/78 and 1/20 MM
patients, respectively. Masood et al. [155] using a lytic IFA
and a whole virus lysate ELISA found that only 2/28 MM
sera were positive. Perhaps as the pathogenesis of HHV-8
becomes better understood this etiological question will
be answered.
5.E.c. Other diseases
Although there are many reports for other diseases and
their possible associations with HHV-8, the data are
sometimes circumstantial and weak, and many have not
been confirmed by extensive investigation in large num-
bers of patients. Only a few selected diseases or conditions
variably associated with HHV-8 are summarized below.
Bone marrow failure is a non-neoplastic disease possibly
associated with HHV-8 observed after kidney and autolo-
gous peripheral blood stem cell transplants. HHV-8 pro-
duced a syndrome of fever, marrow aplasia and
plasmacytosis; these occurred after primary infection and
reactivation, respectively [104]. Neither patient presented
with KS, but both had HHV-8 sequences detected by PCR
after transplantation and at the presentation of
symptoms.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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HHV-8 infection has been associated with congestive
heart failure in both KS and PEL patients [138]. Serologi-
cal evidence has also indicated that Italian patients with
cardiovascular disease have a higher prevalence of HHV-8
and HHV-8 DNA has been found in atheromatous
plaques [156]. Other studies have suggested possible asso-
ciations with HHV-8 and pemphigus vulgaris and pem-
phigus foliaceus [157] and germinotropic
lymphoproliferative disorder [158], but not primary cen-
tral nervous system lymphomas [159].
5.F. Treatment of HHV-8 infection
No single treatment has been found to be completely effi-
cacious for HHV-8 infection. Anti-herpetic drugs such as
foscarnet, ganciclovir, cidofovir, and acyclovir inhibit the
viral DNA polymerase [107] which, therefore, only allows
treatment for replicating viruses in the lytic phase of infec-
tion; latent viruses are unaffected. For example, although
cidofovir was effective in vitro against BCBL-1 cells [160],
intralesional injections were not helpful in reducing the
KS tumor burden [161].
Chemotherapy and/radiotherapy are successful treat-
ments for CKS but HHV-8 DNA has been shown to
remain at the site of the healed lesion [162]. This might
explain the observed reoccurrences of CKS. Treatment for
AIDS-KS has centered on HAART. Studies have shown
marked decreases in the incidence of AIDS-KS since the
use of HAART [163]. However, this reduced risk has been
only with triple therapy, and not double or single anti-
HIV drug therapy [163]. Additionally, HAART seems to
have the best effect on early stage AIDS-KS [164,165];
nonetheless, an 81% reduction in death due to AIDS-KS
was observed though HAART [164].
Finally, because HHV-8 can be transferred from organ
donor to recipient, the possibility exists that CTLs derived
from the donor can be harnessed to provide immuno-
therapy for the recipient [100]. This has been shown to be
an effective treatment for PTLD in the context of EBV reac-
tivation after bone marrow donation [166].
6. HHV-8 Epidemiology
6.A. Serologic prevalence of HHV-8 geographically and in 
major risk groups
The serologic prevalence of HHV-8 infection has been
explored in most continents worldwide and in different
populations at different levels of risk of HHV-8 infection.
It should be noted that the comparisons of prevalence are
limited by whether antibodies to latent or lytic HHV-8
antigens were detected and the test formats used.
6.A.a. North America
Studies from populations from the North American con-
tinent have revealed large differences in HHV-8 preva-
lence between specific populations. Blood donors (BD)
have been found to exhibit different levels of infection
ranging from no detected infection [167] to as high as
15% [168], with more intermediate levels (~5%) found in
most studies [34,59,79]. Individuals infected with HIV
infection or having AIDS had more elevated prevalences
of 30%–48% [34,74,167], although one study found no
evidence of HHV-8 infection in their small HIV cohort
[167]. Homosexual men showed prevalences ranging
from 20%–38% [74,169,170]. In contrast, the highest
prevalences, between 88% and 100%, were found in those
patients with KS [34,79,167]. Other miscellaneous popu-
lations, such as healthy individuals, the elderly, and those
infected with EBV showed a range of 0%–8.6%
[74,167,171]. IVDUs had relatively higher prevalences of
10% in both heterosexual men and women; the longer the
patient's injected drug use, the higher was the risk of
HHV-8 infection, which was not dependent upon sexual
behavior or demographic differences [169]. Of note is the
exceptionally high level of infection found in children in
south Texas, 26% [172]. One report from Quebec, Can-
ada, did not find evidence of HHV-8 infection in 150
renal transplant patients [173].
6.A.b. The Caribbean and Central America
The prevalence of HHV-8 in BDs from Jamaica, Trinidad,
and Cuba was 3.6%, 1.2%, and 1.2%, respectively
[34,174,175]. Persons with HIV infection from Trinidad,
Honduras, and Cuba possessed prevalences of infection at
0%, 24%, and 21%, respectively [34,175,176]. Compared
to other studies in KS patients, a relatively low prevalence
of HHV-8 infection was found in AIDS KS samples from
Cuba (78%) [175]. A very low level of infection was found
in attendees of a gynecology clinic in Jamaica (0.7%)
[174], but an elevated prevalence was seen in healthy indi-
viduals in Honduras (11%) [176]. Commercial sex work-
ers in Honduras showed 19% infection [176].
6.A.c. South America
Evidence of HHV-8 infection has been discovered in
South America in at least four countries. In indigenous
populations, those without specific risk factors, preva-
lences of 53% were found among Brazilian Amerindians
[177], 16% in northern Brazil [178], and 36% in Amerin-
dians of Ecuador [179]; the prevalences in Ecuador ranged
from 20%–100% depending upon the tribe tested [179].
The HHV-8 prevalence was much less in BDs in Brazil
(2.8%), Chile (3.0%), and Argentina (4.0%); although in
Argentina the prevalence in BDs ranged between 2.4% –
4.3% in three different locales [180]. In contrast, Sosa et
al. [181] reported that in Argentinean HIV+ IVDUs, 17.4%
showed HHV-8 seropositivity; where as, in HIV negative
IVDUs the prevalence was lower at 11.1%. Still lower, HIV
negative heterosexuals with no IVDU behavior had a
prevalence of 5.7%, similar to that found by Perez et al.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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[180]. AIDS-KS patients in Brazil had a prevalence of 80%
[182].
6.A.d. Europe
In Europe, excluding Italy and its surrounding islands, the
prevalence of HHV-8 in BDs was not above 6.5% in six
countries: Hungary 0.83%–1.6%, Switzerland 5%, the
United Kingdom 1.7%, France 2%, Spain 6.5%, and Ger-
many 3% [59,83,183-186]. In healthy individuals in Swit-
zerland, Greece, and Albania, evidence of HHV-8
infection was 13%, 12%, and 20% [59,184,187]. Persons
infected with HIV ranged from a low of 16% in women in
Germany to a high of 31% in homosexuals in the United
Kingdom [59,184,186]. Homosexuals in Spain however,
had an 87% prevalence [185]. IVDUs and persons with
STDs in the United Kingdom, Spain, and France showed
prevalences of 3.2%–8.4%, 12%–17%, and 13%, respec-
tively [59,185,188]. Similar to North America, the HHV-8
prevalence in patients with classic or endemic KS was
75%, 94%, and 100% in Hungary, Greece, and France,
respectively [59,83,183]. The HHV-8 prevalence in AIDS-
KS patients in Switzerland (92%), the United Kingdom
(81%), France (80%), and Germany (100%) were similar
to the prevalence of HHV-8 in classic KS in Europe
[59,83,184,186]. IVDUs in the United Kingdom and
Spain had prevalences of 0.0%–3.2% and 12%, respec-
tively [59,185].
6.A.e. Italy/Sardinia/Malta/Sicily
Estimations of seroprevalence in Italian BDs were con-
founded by the variable geographic prevalences and the
type of antibodies being detected. Whitby et al. [189]
showed that the overall prevalence in 747 BDs in Italy was
14%. However, when these individuals were segregated by
North/Central Italy and Southern Italy, the levels of HHV-
8 infectivity dispersed to 7.3% and 24.6%, respectively.
Even in Rome, centrally located in the country, the preva-
lence in BDs varied from 2% of people with latent anti-
bodies to 28% with reactivity to lytic antigens [190].
Other reports found prevalences in BDs to be between
3.5% to 18.7% [167,191,192]. In the general population
of Sardinia [61], Sicily [193], and for the elderly in Malta
[194], antibodies to HHV-8 were found in 11%, 20%, and
as high as 54%, respectively. In Italy, those infected with
HIV showed a 14% prevalence for latent antibodies, but as
high as 61% for lytic antibodies [190]; an intermediate
rate (25%) in HIV+ persons was observed by Calabro et al.
[192]. In Sicily, 34.6% of HIV+ patients had HHV-8 infec-
tion [193]. In regards to other STDs, infections with syph-
ilis were accompanied by HHV-8 infections with 37%–
76% showing coinfection, whereas those free from syphi-
lis infection only showed 11%–46% prevalence [190]. No
significant differences were seen in persons with or with-
out HCV infections, 10%–50% and 16%–47%, respec-
tively [190]. Perna et al. suggested that the relatively low
prevalence of HHV-8 in drug addicts in Sicily (16.6%) was
indicative of the poor transmission of HHV-8 parenteraly
[193]. Calabro et al. [192] observed 61.5% prevalence in
HIV+ homosexuals in Italy, but this rate might have been
confounded by the coinfection of HIV because Perna et al.
found a lower rate in homosexual men, 32.6% in Sicily
[193]. Even healthy adults in Sicily had an elevated prev-
alence beyond that found in BDs with 36.2% observed
with HHV-8 infection [193]. For this central region of the
Mediterranean, the prevalence of HHV-8 in CKS normally
exceeded that of AIDS-KS. CKS in Italy and Sardinia
showed evidence of infection in 95%–100% of patients.
However, AIDS-KS were reported to have a much wider
range of reactivity in HHV-8 tests: 71%–79% [167],
57.1%–100% [191], 67%–83% [190], and 100% [192] in
Italy, and 100% in Sicily [193].
6.A.f. Middle East
Healthy individuals in Israel were found to have a HHV-8
seroprevalence of 4.8% [195], whereas individuals with
HBV infection seemed to be at an increased risk of infec-
tion (22% prevalence) [81]. Family members from these
hepatitis patients also had increased prevalence of HHV-8
at 9.9% [81]. When Ethiopian immigrants to Israel were
tested for antibodies against HHV-8, this unique cohort
possessed an elevated presence of antibodies against
HHV-8 [124]. Fifty seven percent of Ethiopians with HIV
infection showed HHV-8 infection, whereas those with-
out HIV had a lower prevalence of 39.1% (P = 0.03). Inter-
estingly, despite the high prevalence of HHV-8 in the
HIV+ individuals, in those with AIDS, the occurrence of
KS was almost nonexistent (0.85%) compared to non-
Ethiopian immigrants with AIDS (12.5%) [124]. Reports
on HHV-8 prevalence from Egypt are scarce. Andreoni et
al. showed data that in teenagers and young adults, 29%
possessed lytic antibodies against HHV-8, but only 5%
had latent antibodies [191].
6.A.g. Asia – Southeast and Asia proper
Blood donors and healthy individuals in five Asian coun-
tries have shown a 3-fold range in HHV-8 prevalence. In
healthy Indian individuals [34], only 3.7% had antibod-
ies, with Thailand, Malaysia, and Sri Lanka exhibiting
prevalences no higher than 4.4% [34]. In Taiwan, lytic
antibodies were found in 11.7% and 13% of the blood
donors tested [196,197]. However, a much higher pres-
ence of prior infection was found in the general popula-
tion of the Uygur people in northwestern China, 47%
[198]. The prevalence of infection in HIV positive individ-
uals in Asia varied widely, as well. Prevalences of HHV-8
infection of 0.6% to 11.2%, 2.4%, and 40% where found
in Thailand, India, and Taiwan, respectively [34,197,199].
Classical KS still had the highest rate of infection, with
83% of patients in Taiwan [197] and 100% in China
[198] showing positivity for HHV-8 antibodies.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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6.A.h. The Pacific region
There have been few studies on the seroprevalence of
HVV-8 antibodies in the Pacific region. Despite this, the
viral infection has been found in both Japan and New
Guinea [200,201]. Fujii et al. [200] found a very low prev-
alence of HHV-8 infection in Japan in BDs where only
0.2% showed reactivity to latent antigen. Comparatively,
persons with HIV infection had an elevated prevalence of
between 9.8% and 11.6%. In New Guinea, Rezza et al.
found a much higher prevalence in the indigenous general
population with approximately 25% of the 150 people
tested showing prior infection [201].
6.A.i. Sub-Saharan Africa
In sub-Saharan Africa, the seroprevalence of HHV-8 was
above 36% in every population reported. In the southern
part of the continent, healthy individuals showed a HHV-
8 prevalence of 37.5% in Zambia [34], and 54.7%–90%
in Botswana, depending upon the test used [179,194]. In
Zambia, the HHV-8 prevalence was comparable for HIV+
persons (44%) [34] and 51.1% in HIV+ pregnant women
[202]. Cancer patients, in general, in South Africa also had
a high prevalence of 36.3% [203]. In comparison, patients
with AIDS-KS exhibited a prevalence of 83% in South
Africa [203] and 92.3% in Zambia [202].
Central African nations also had HHV-8 prevalences in
keeping with those observed in the south. In the Congo, a
high prevalence in healthy individuals, 69%–79%,
showed prior HHV-8 infection [194]. Somewhat lower
percentages were found in healthy individuals in Ghana
(41.9%) [34], in Uganda (38.7%) [34], 51%–62% [167]),
and 55.5% in Cameroonian pregnant women [83]. Simi-
lar HHV-8 prevalences were found for HIV+ persons in
Uganda with between 45.7% and 71% HHV-8 prevalence
reported depending upon the study and the test used
[34,59,167]. The prevalence of HHV-8 infection in AIDS
KS patients was relatively higher but did not reach 100%;
in Uganda, Gao et al. reported 78% and 89% [167] and
Simpson et al. found 82% prevalence [59].
In conclusion, prevalence rates varied depending on the
geographic origin of the sera tested and the specific tests
used to determine these prevalences; in particular,
whether antibodies against latent or lytic antigens were
detected could make a difference in the results. Addition-
ally, it is unclear whether these differences were truly due
to varying prevalence rates, or perhaps to a lack of sensi-
tivity and specificity of the serologic assays, as has been
shown for HIV [204] and HCV [205]. Because most
reports indicated high rates of HHV-8 infection in persons
with KS, regardless of their origin, it is probable that the
assays possess reasonable ability to detect true infection.
6.A.j. Risks of age related HHV-8 infection
Regamey et al. reported that there was a trend of increas-
ing HHV-8 antibody prevalence to Orf 65 antigen with
increasing age in HIV negative individuals in Switzerland
[184]. Below 30 years of age, the prevalence increased
from 15% to 23% and then to 50% in the next three dec-
ades. A similar effect was observed in BDs in Hungary
[183]. As age increased from 19 until 25 years of age and
then for every decade afterwards, the distribution of sero-
positivity to LANA increased moderately, but significantly
(P = 0.048). A similar association was observed with Orf
65 peptide reactivity but the numbers of subjects were too
small to calculate statistical significance [183]. In Taiwan,
increased progression of antibody response against HHV-
8 lytic antigens was observed, starting with a low of 3% in
children under five years of age and peaking between age
31 and 40 (19.2%) [196]. Many more examples of this
have been reported in Africa [83,128,203], Sardinia [61],
and Italy [192]. Perna et al. [193] and others
[172,183,185,192] have shown that there most likely
exists non-sexual routes of HHV-8 transmission because
children worldwide have been infected by HHV-8.
6.B. Molecular prevalence of HHV-8 genotypes and 
variants
From DNA sequence analysis of distinct loci derived from
60 HHV-8 isolates, the clustering of four major HHV-8
viral subtypes was discovered [206]. These subtypes, A, B,
C, and D are based upon DNA sequence derived from the
K1 gene, a glycoprotein with transforming properties
[207,208], and they exhibit 30% amino acid (aa) variabil-
ity. These aa substitutions result from an 85% nucleotide
substitution rate in this highly variable gene. The four sub-
types were further divided into another 13 clades by Hay-
ward [206]. The A1, A4, and C3 variants were
predominant in the US AIDS KS samples, but the B variant
was predominant in samples from Africa. C variants were
observed from samples from Saudi Arabia and Scandina-
via. The D subtype was uncommon and was found only in
classic KS patients in the Pacific region. Another gene,
K15, showed two different alleles (P and M), but these
allelic types were not associated with the K1 subtypes
[206]. These different genotypes have been investigated to
explain the possible pathogenic and epidemiologic varia-
tion seen with HHV-8 infection [125]. Studies that are
more recent have expanded upon previous work and have
shown that the K1 locus can be divided into six subtypes
with 24 clades showing strong linkage to the geographic
origin of the particular isolate. Data have shown that sub-
types A and C are prevalent in Europe, the U.S.A., and
northern Asia. Subtypes B and A5 predominate in Africa
and the D variant is found in the Pacific. Subtype E has
been discovered in Brazilian Amerindians and a unique
subtype Z was found in Zambia [125]. In a recent study,
Whitby et al. characterized the K1 hypervariability fromVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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general populations in South America and Africa: i.e.,
those without any obvious symptoms of HHV-8 infection
[179]. Amerindians from Ecuador carried the E subtype,
in keeping with previous studies from South America. In
Botswana, subtypes B and A5 were exhibited by subjects
from the Bantu and San tribes, similar to the subtypes
found there from KS patients. These results show that the
same HHV-8 viral strains from similar geographic regions
can be found in both diseased and non-diseased individ-
uals, suggesting that there is no association between cer-
tain genotypes and disease.
7. HHV-8 Gene Products of Diagnostic 
Importance
7.A. Orf 73 (LANA1) latency protein
Immunofluorescent observations that PEL cells exhibited
a distinct nuclear immunofluorescence after challenge
with antisera from KS patients, led to the identification of
Orf 73 as the gene responsible for the latency associated
nuclear antigen-1 (LANA1) [209-211]. Early gene align-
ments had suggested that Orf 73 was an immediate early
gene with 51% similarity to the Orf 73 of HVS [19]. Stud-
ies have since shown that LANA1 is a 222–234 kDa pro-
tein that is expressed in the majority of nuclei in KS
spindle cells [211,212]; however, the LANA1 protein
expression is variable [211] and can depend upon the
clinical stage of the KS tumor [213]. The immunodomi-
nant epitope has been mapped to the C-terminal domain
of the protein [210]. The gene is under latent control as
evidenced by reduction in Orf 73 mRNA after chemical
induction of the viral lytic phase [210]. The antigenicity of
the recombinant LANA1 protein has been shown by West-
ern blot; over 70% of HHV-8 IFA seropositive sera were
LANA1 positive in the Western blot [210,211].
7.B. Orf 65 capsid protein
Orf 65 was identified by Russo et al. [19] as a lytic capsid
protein with less than 60% similarity to similar capsid
proteins from HVS and EBV, but is not cross-reactive with
HVS and EBV capsid proteins [59,214-216]. Orf 65 has
been shown to be the smallest component of the HHV-8
capsid with a predicted basic isoelectric point of 9.6, sim-
ilar to other herpesviruses [217]. Because of its embossed
structural position on the capsid, Orf 65 might be
involved in interactions with the viral tegument and cellu-
lar proteins upon infection [218]. First cloned in bacteria
by Simpson and colleagues [59] and subsequently by oth-
ers [215], Orf 65 is a highly antigenic 18–22 kDa protein
against which more than 81% of KS patients are seroreac-
tive [59,215]. The dominant eight amino acid epitope has
been mapped to the C-terminus, and allowed develop-
ment of a peptide assay with reactivity in 90% of the KS
samples tested [216].
7.C. K8.1 glycoprotein
Originally identified as a single gene locus [19], research
has since shown that K8.1 is derived from spliced tran-
scripts [219] for which the transmembrane sequence is
appended [220]. This glycoprotein is unique to HHV-8
and is a TPA-inducible lytic protein [221]. On Western
blots from induced PEL cells, it measures between 35–40
kDa with the characteristic smear of a glycoprotein [221].
Immunoelectron microscopy suggests that the virion
acquires the K8.1 glycoprotein at the cell plasma mem-
brane while budding from the host cell [222]. Two tran-
scripts are produced, K8.1A and K8.1B, of which K8.1B is
the shorter by dint of an internal deletion of 61 amino
acids. K8.1A, casually referred to as K8.1, is very antigenic,
with 97% of HIV+, KS+ patients having antibodies
directed against it on Western blot; in HIV+, KS-, persons
61% showed reactivity [219].
7.D. Other antigenic proteins
Orf 25 and Orf 26 code for other major and minor HHV-
8 capsid proteins, respectively, and were investigated for
their diagnostic utility [223]. Orf 25 possesses 68% iden-
tity to the EBV BCLF1 major capsid protein and exhibited
considerable cross-reactivity to EBV+ sera and was not
used further in their studies. However, Orf 26 has only
49% identity to its EBV gene homologue and showed no
cross-reactivity [223]. Only one third of KS patients were
reactive to Orf 26, although some exhibited an increase in
IgM and IgG reactivity 15 months prior to KS disease.
The Orf 59 protein is another HHV-8 protein that has
shown modest diagnostic importance in a few investiga-
tions. This gene has about 50% similarity with its HVS
and EBV homologues and is presumed to be a DNA repli-
cation protein in those viral systems [19]. Orf 59 is a 50
kDa protein with characteristic early-late lytic expression
patterns seen for other viral proteins necessary for viral
DNA replication [224]. The protein has been localized to
the nuclear membrane via IFA and is observed in approx-
imately 30% of induced PEL cells, but in less than 8% of
uninduced cells [224]. The Orf 59 gene product, proces-
sivity factor-8, has been shown to be present in AIDS-KS
tumors (50%) although perhaps not in as many spindle
cells as Orf 73 [225]. Approximately 30% of AIDS-KS
patients had antibodies against this antigen [226]. Orf 59
might be helpful in identifying aggressive KS disease
[225,226].
8. HHV-8 Diagnostics
8.A. HHV-8 serological diagnostics
Presently, the diagnosis of KS requires clinical and histo-
logic evaluation; however, the increasing documentation
of its association with HHV-8 has raised the important
possibility of being able to predict disease occurrence by
demonstrating HHV-8 infection [55]. Additionally, thereVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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is a need to develop sensitive and specific serological
assays to detect antibodies to HHV-8 for possible blood
bank screening, assisting in clinical diagnosis, and in
research to facilitate the understanding of the scope of this
virus's association with rare, but nonetheless life threaten-
ing malignancies. HHV-8 infection can be identified by
polymerase chain reaction in tissues and in cells; however,
amplification methods are expensive, time consuming,
and have been shown to be lacking in sensitivity for easily
accessible diagnostic specimens such as plasma and
PBMCs [177]. Alternatively, the testing for specific anti-
bodies to HHV-8 offers a simple, inexpensive, and effec-
tive means to document infection and a help to define the
relationship between infection and disease progression
and yield insight into pathogenic mechanisms.
Currently, four methods have been used to demonstrate
antibodies to HHV-8: enzyme-linked immunosorbant
assay (ELISA), immunofluorescent assay (IFA), Western
blot, and immunohistochemistry (IHC). Detection of
infection and determination of seroprevalence can be
dependent upon which test is selected [227]. ELISA meth-
ods vary according to the HHV-8 antigens used and
whether they are recombinant antigens, viral lysates, or
synthetic peptides. IFA methods incorporate virally-
infected cell lines, either latently infected with expression
of LANA1, or cells that express lytic antigens following
chemical induction (i.e., those representing viral replica-
tion). The Western blot technique utilizes electrophoreti-
cally separated virally infected cell lysates or whole viral
lysates, with transfer to nitrocellulose and then subse-
quent detection of reactive antigens; it has the advantage
of identifying the presence of antibodies to specific anti-
gens. IHC on fixed cells and tissue allows to determina-
tion of which cells harbor the virus in vivo and semi-
quantitative analysis of infected sell type to help learn
more about pathogenesis. IHC is also useful to confirm or
rule out the clinical diagnosis of KS. These tests are
explored in the following sections.
8.A.a. HHV-8 antigen sources
PEL cell lines have been important sources of antigen
mainly for use in IFAs, but also in the form of cell lysates
for Western blotting and tools for investigations into
HHV-8 pathogenesis [59,210-212,215,224,226]. Over 12
PEL cell lines have been established and they each contain
50–150 episomal copies of HHV-8 per cell [8,132-136].
About half are coinfected with EBV (e.g., BC-1, BC-2,
BCBL-2), but others have only latent HHV-8 infection
(e.g., BCBL-1, BC-3, KS-1) [135]. Induction of viral repli-
cation can be initiated by sodium butyrate (butyrate
[228], 12-O-tetradecanoylphorbol-13-acetate (TPA), a
phorbal ester [229], or less commonly hydrocortisone
[130]. Cell cultures derived from KS spindle cells are not
good material for HHV-8 diagnostics because they lose
the virus after 2–6 passages [230].
Other sources of antigen have been whole virus lysate,
which has been used successfully in the ELISA format
[231]. After induction of a PEL cell line, the whole virus is
usually purified over a sucrose gradient. The drawback of
this method is that it preferentially selects for lytic anti-
gens and does not allow detection of latent antibodies
such as LANA1 [112]. In contrast, individual HHV-8 pro-
teins have been incorporated into tests by either express-
ing them as recombinant proteins or as synthesized
peptides. Recombinant proteins such as Orf 65, K8.1, Orf
25, and Orf 26 have been expressed in easy to grow bacte-
rial systems [59,221,223]. Antigenic proteins have also
been expressed in more difficult to grow baculovirus sys-
tems (insect cells) [232,233], but they have the added
benefit of protein glycosylation which bacterial cells can
not perform. It has also been reported that LANA1
(Orf73), because of its large size (>200 kDa) is expressed
better in insect cells (personal communication, Dr. D.
Whitby, NCI-Frederick). Synthesized peptides of immun-
odominant portions of antigenic proteins (e.g., K8.1, Orf
65) have been developed as a strategy to streamline the
production process and to reduce non-specific reactions
[183,234].
8.A.b. ELISAs for the detection of HHV-8 infection
ELISA tests are easier to manipulate and technically are the
test of choice for large-scale seroprevalence studies. ELISAs
based on recombinant antigens of HHV-8 have shown
that a specific humoral response is produced against cap-
sid proteins of HHV-8, allowing identification of HHV-8
infection [59,92,223]. Recombinant proteins derived
from a truncated Orf 65 minor capsid gene have been
used with a relatively high degree of success to differenti-
ate populations of KS patients from BDs [214]. Similarly,
recombinant proteins derived from the Orf 25 and Orf 26
genes (major and minor capsid proteins) have been used
in ELISA assays to detect IgG and IgM antibodies, but with
a lesser degree of success [223]. Seroconversion against
capsid proteins has been shown to occur in less than one
year after infection using an Orf 65 ELISA [92].
An ELISA based on viral lysate antigens of HHV-8 has also
produced encouraging results [231]. Although this assay
demonstrated a good sensitivity for detecting infection in
patients with classical KS (CKS) and AIDS-KS (80%–
90%), normal healthy blood donors had 2–11% preva-
lence. This ELISA also possessed the ability to differentiate
populations based on antibody titer; the mean titer in
blood donors was 1:30, while titers ranged from 1:6000 to
1:15000 in AIDS-KS and CKS patients.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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Encouraging results have come from a recombinant ELISA
based upon the K8.1 gene product [235] and has been
considered one of the more sensitive tests with acceptable
specificity. Immunodominant peptides from the Orf 65
and K8.1 antigens were incorporated in an ELISA format
and used successfully to measure the risk factors in
women [76] and to identify HHV-8 infection in allogeneic
stem cell transplant patients who are at risk of KS because
of their immunocompromised status [236].
Initially, the primary method of detection of latent anti-
bodies was using the LANA IFA, however, subsequent
cloning of Orf 73 (LANA) and its application in the ELISA
format has begun to replace the LANA IFA. The Orf 73
ELISA has been found to possess the same high specificity,
but with a 10% increase in sensitivity [107]. The Orf 73
ELISA has found utility in gauging the progression to KS
in HIV+, HHV-8 infected persons [43]. In that study,
increasing titers to Orf 73 over time were associated with
HIV+ patients acquiring KS.
8.A.c. IFA for the detection of HHV-8 infection
IFAs are a common method to identify antibodies to
HHV-8. To detect latent antibodies, an HHV-8 infected
PEL cell line (e.g., BCP-1, BCBL-1, BC-3, KS-1) is used to
measure antibodies to the primary latent antigen, LANA1
or ORF 73 [107]. This latent antigen corresponds to a
~234 kDa nuclear antigen, which has been shown to be
recognized by sera from KS patients [211], and is charac-
terized by its speckled nuclear fluorescent signature in
95% of PEL cells [107]. With this assay, seroprevalences
have ranged from 2%–27% in several studies of blood
donors where KS is endemic, but lower (0%–15%) for
those geographic regions where KS is mainly associated
with AIDS and transplant patients [227]. However, the
LANA1 assay has been shown to be relatively insensitive
and therefore might not be the best choice of assay to
screen low titered populations [235].
Lytic antigens can be expressed by these cells following
induction with a TPA or with butyrate [237] and have pro-
duced encouraging results. The number of induced cells is
dependent upon the cell line used, the time of induction,
and the chemical used to induce the cells [107,238]. Stud-
ies using induced PEL cell lines point to much higher fre-
quencies of infection than have been suggested by
serology based on latent proteins in populations not at
risk for sexually transmitted diseases [16,239]. However,
other studies using lytic IFAs have also indicated that there
are higher levels of HHV-8 infection in otherwise healthy
individuals [227] and infection would be spread by non-
sexual routes in these cases. As with the ELISA, the IFA has
been used to determine antibody titers, with sera from
HIV-positive persons with KS demonstrating higher titers
to lytic and latent antigens as compared to individuals
without KS [214,231]. This test method is relatively more
sensitive to serum dilutions that are not extensive enough;
the correct serum dilution is important to correctly differ-
entiate true positive reactions from those that are non-spe-
cific [112,214].
8.A.d. The diagnostic utilities of the Western blot
Western blots using purified viral lysates of HHV-8 have
been used to identify immunodominant proteins using
sera from pre- and post-KS patients [114,221,240]. This
method has shown utility in the diagnosis and prognosis
of KS, but it is more cumbersome and expensive than
other serologic assays. A 35–37 kDa glycoprotein has been
a protein most frequently and intensively detected, and
corresponded to the K8.1 Orf of HHV-8 [220].
In a review of articles that used Western blot in their inves-
tigations of HHV-8, only four dealt with antigen identifi-
cation or expression. These reports could influence the
development of a confirmatory Western blot as they
showed: 1) There are different antigen profiles in diseases
associated with HHV-8 [140]. 2) HHV-8 possesses the
glycoprotein, gB, found in other herpesviruses and might
be a candidate antigen [241]. 3) That different risk groups
and different stages of disease could exhibit different anti-
body profiles [242]. 4) Patients undergoing antiviral ther-
apy might not produce certain antibodies due to a
decreased expression of HHV-8 antigens [238]. These
findings suggest that it might be necessary to identify spe-
cific antigens for use at specific times of infection and even
for different disease states.
Nine reports involved the use of Western blots for screen-
ing purposes [61,94,210,219,221,226,243-245]. Recom-
binant Orf 65 was used most often followed by K8.1, Orf
59 and Orf 73, and finally vIL-6 and Orf 47; however,
there was no utility in using vIL-6 or Orf 47. In these
reports, KS sera were detected by K8.1 with the greatest
sensitivity, followed by Orf 65 and then Orf 73. In these
studies, there were not sufficient HIV+ sera examined to
draw conclusions as to which antigen was best in that spe-
cific population. Sera/plasma from healthy controls var-
ied from a low of 0% for Orf 59 and Orf 73 to 6.5% for
K8.1 and 8.3% for Orf 65.
Eleven research reports utilized Western blots as tools to
confirm the results of previously run serological assays
[59,92,183,232,246-252]. Most of these authors used the
same antigen found in the ELISA as the confirmatory anti-
gen in the Western blot; however, two reports had the
Western blot confirm IFA results. In seven instances, the
authors used the Western blot to confirm a single screen-
ing assay and in four reports, they used the Western blot it
to resolve a disagreement between two screening assays or
in duplicate samples.Virology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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More recent reports have continued to use the Western
blot as both a primary assay and as a confirmatory test
[175,253]. The Western blot method has the benefit of
allowing identification to one or more antigens. With
accessibility to multiple recombinant proteins now possi-
ble, several researchers have developed recombinant
Western blot utilizing more than one protein [197,254].
In those reports, they accepted reactivity to one of three
antigens to be a marker of HHV-8 infection. In this man-
ner, Wang et al. proposed a new antigen, Orf 57, for use in
asymptomatic populations [197]. Clearly, despite the
technical difficulties in producing Western blots, they are
a useful, multitasking serological method in HHV-8
diagnostics.
8.A.e. Comparisons and concordances between assays
Estimates of the prevalence of HHV-8 by different ELISAs
have varied. This variance has been shown in reports of
multicenter or multitest studies. Spira et al. [255] found a
range of concordance between 69% and 94% using seven
serologic tests with Kappa values as low as 0.387 (fair
agreement) and as high as 0.909 (almost perfect). Rabkin
et al. [256] also evaluated seven serologic tests and found
a range of concordance between 50% and 94%, with
Kappa statistics ranging from -0.08 to 0.86, indicating that
the interassay correlation between the assays was less than
favorable. The tests frequently disagreed on individual
sera, particularly from blood donors. It was concluded
that current antibody tests for HHV-8 have uncertain accu-
racy in asymptomatic HHV-8 infection and that addi-
tional tests to define the actual prevalence may be
required. Poor correlation for positive results has been
observed in other studies [257]. Second generation tests
seem to provide better concordances, although the best
results came from IFA tests rather than ELISAs in one mul-
ticenter study [258]. Even with more optimized assays,
sensitivity and specificity can be insufficient for clinical
use [235]. As with the detection of infection by many
viruses (e.g., HIV), sequential use of screening and con-
firmatory tests for HHV-8 are likely to be required to
address sensitivity and specificity issues; accordingly, an
testing algorithm has been reported [235]. These findings
supported the need for critical investigation of the param-
eters that could influence the performance of these tests.
Although there is some variability in prevalence among
similar populations with the same test, most data show
that there is agreement within a defined range. The lack of
concordance in HHV-8 diagnostic assays occurs primarily
because not all HHV-8 infected persons exhibit all anti-
bodies against all HHV-8 antigens at the same time [259].
This phenomenon of single antibody reactivity is much
more apparent in populations who are at low risk of infec-
tion, such as blood donors [259]. Because of this, specifi-
cities are more variable than sensitivities among different
laboratories [259].
Although refinement of the diagnostics assays is still pos-
sible, the greatest chances of success are in developing
algorithms that make use of multiple assays for screening
and then confirmation or alternatively, the use of assays
that incorporate multiple antigens which have been
shown to be highly immunogenic, perhaps during differ-
ent stages of infection [259]. It is possible to use a combi-
nation of latent and lytic antigen tests to determine a true
positive as has been employed by several laboratories
[112]; however, recent data indicate that the humoral
response to HHV-8 does not always produce both latent
and lytic responses at the same time [260]. In addition,
antibodies directed against lytic antigens seem to be more
prevalent than those for latent antigens.
8.A.f. IHC for the detection of HHV-8 infection
IHC is a powerful serologic tool, but like Western blots
can be tedious to perform. In the field of HHV-8 research
and diagnostics, IHC has been used to locate HHV-8 pro-
teins, assess involvement of HHV-8 in malignancies,
detect specific HHV-8 gene expression, and to provide
diagnosis of KS. The ability to identify which specific cell
types or structures within a cell are expressing HHV-8 pro-
teins can assist in the understanding of HHV-8 pathogen-
esis [261,262] and determine the possible etiology of
malignancies [263-267]. Detection of specific HHV-8
gene expression, in particular LANA1 [140,211], has led
to possible clinical applications for the diagnosis of KS in
tissue samples [268,269]. This allows the exclusion of
other neoplasms that can mimic KS [268-270]. The ability
of monoclonal and polyclonal antibodies to localize spe-
cific HHV-8 antigens should continue to improve HHV-8
diagnosis and our understanding of HHV-8 pathogenesis.
8.B. HHV-8 molecular diagnostics
The diagnostic benefit of the polymerase chain reaction
(PCR) for herpesviruses other than HHV-8 has been
mixed. Studies have shown a lack of correlation with PCR
and positive serological tests results for viral retinitis [271]
and no herpesvirus sequences were discovered in the
PBMCs of suffers of chronic fatigue syndrome (CFS)
[272]. Other studies, however, have found PCR to be use-
ful in diagnosing HHV-6 infection in exanthum subitum
during convalescence where IgM is no longer detected
[273]. In general, Pearson et al. recommended the use of
PCR to better diagnose acute infection or reactivation in
herpesvirus infections unless sentinel antigens could be
identified [274]. For the detection of HHV-8, the PCR
method with optimal performance should fulfill several
conditions. The test should be specific for DNA sequences
found only in the HHV-8 genome and not other herpesvi-
ruses. The K-genes might be good candidates for this, andVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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indeed a real-time PCR test using the K6 region has been
used [177]. Sensitivity is an absolute requirement because
the virus is found at such low copy numbers due to its
latent biology. Most reports have indicated sensitivities
from 1–100 copies per reaction [275]. However, the her-
pes-specific biology makes sampling error a concern.
Therefore, strategies are needed to detect the virus in
latency, such as induction of the lytic cycle before DNA
isolation. There have been a few reports where this has
been attempted with success [48,58]. If nested PCR is to
be used to gain the needed sensitivity, exceptional care
must be taken to avoid false positives. However, nested
PCR has the power to provide added specificity and con-
firmation by amplifying two separate amplicons in the
nested PCR reaction. Alternatively, multiplexing in real-
time PCR, with the proper optimization and design, could
provide this needed level of surety. An easily obtainable
diagnostic sample would complete the diagnostic strategy
to maximize the effectiveness of PCR for the detection of
HHV-8. Reports have shown that saliva contains the high-
est prevalence of virus in HIV negative persons [56] and in
samples from HIV+ patients it is equivalent to PBMCs
[51,56]; therefore, it should be considered the sample site
of choice. Saliva collection devices are already commer-
cially available (OraSure, Bethlehem, PA) and FDA
approved for serologic testing and might be convertible
for use for PCR. Finally, the ability to quantify HHV-8
viral loads using quantitative real-time PCR has been
employed to measure HHV-8 viral burdens to investigate
the association of viral load and progression to KS
[276,277] and the pathogenesis and transmission of
HHV-8 [86,278].
In a review of the literature, the use of molecular diagnos-
tics, in particular PCR, for the detection of HHV-8 infec-
tion has been less than optimal. In most cases, serology is
the preferred method to identify HHV-8 infection. Most
articles have shown that at least one serological assay had
better sensitivity than PCR on the same samples, even bet-
ter than nested PCR. For example, in a study of AIDS-KS,
IFA was able to detect HHV-8 antibodies in 50% (latent)
to 100% (lytic) of the patients, whereas, nested PCR
detected infection in only 33% [57]. The data from a
minority of reports showed that PCR was a more favorable
assay in isolated cases [279] or that serology and PCR were
comparable [280]. In a composite set of 642 samples from
numerous reports, 69% were concordant in their PCR and
serology results. However, 179 samples (28%) were posi-
tive by serology, but PCR negative; only in 21 samples
(3.3%) was there a PCR positive result without a corre-
sponding positive serology.
The utility of PCR in detecting HHV-8 in KS patients is bet-
ter but not perfect. PCR appears to be very useful when
detecting HHV-8 directly in the KS lesions, with sensitivity
approaching 100% [50,51,183,279]. However, PBMCs
from KS patients were observed to have fewer instances
(~50%) of detectable viral sequences [50,51,55]. Detec-
tion of HHV-8 DNA by PCR in the PBMCs of HHV-8
infected individuals is not a common event. Only 10–
20% of seropositive persons have detectable HHV-8 DNA,
but this percentage increases with evidence of KS disease
and more severe disease [259]. Even in KS lesions, if the
tissue sample is not processed correctly for PCR, there can
be false negative results [259]. However, PCR has been
found to be useful in detection of early infection or reac-
tivation, especially at times of clinical sequelae of viral pri-
mary infection or reactivation [49].
Few reports have used plasma or sera as the analyte for
PCR, especially juxtaposed to serological methods
[49,56]. However, these investigators seem to indicate it
does not perform any better than PBMCs. It is noteworthy
to add that several authors observed HHV-8 viremia to be
intermittent. In longitudinal samples, several investiga-
tors have found that despite enhanced detection schemes
and serial samples over periods of time exceeding two
years, detection of HHV-8 in PBMCs can be missed 30%
of the time or more [54,57,58,281,282]. Even in saliva,
which has been shown to carry a relatively higher viral
burden, due to intermittent shedding up to 65% of the
time, detection of the virus can be missed if only single
samples are relied upon for diagnosis [51,56]. Finally, in
serum/plasma, detection of can be intermittent with per-
haps the best chance of detection at signs of clinical dis-
ease [49,54].
Reports on the use of in situ hybridization and reverse-
transcriptase PCR (RT-PCR) have been used as mainly
research tools to investigate associations of HHV-8 and
specific diseases [29,267]. Most RT-PCR reports were con-
cerned with detecting mRNA transcripts to determining
infectivity [283] or as a diagnostic method in HHV-8
related disorders, such as PELs [284]. There have been few
reports using nucleic acid sequence-based amplification
(NASBA) assays to detect and quantitative HHV-8 viral
loads in HHV-8 diseases [285,286], although the reports
seem to confirm the findings from quantitative PCR stud-
ies that increased viral load in to be expected in more
advanced KS, both in the lesions and in the PBMCs.
8.C. Commercial sources
Although HHV-8 has been associated with only a few dis-
eases, commercial sources for both testing and kits are
available. These include molecular and serologic testing
from established laboratories and hospitals, although
PCR seems to be the method most used (Table 2). IFA or
ELISA serologic kits are also commercially available
(Table 3), but no companies seem to be marketingVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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molecular kits except for Celonex, which produces a
microarray system for herpesviruses.
9. Current Diagnostic Issues
Current HHV-8 diagnostic tests are not commonly used in
the clinical arena because their procedures are not stand-
ardized and the specific patient populations to which they
would best be applied are not clearly identified. Investiga-
tors have not been able to unambiguously determine if
low risk individuals, such as blood donors, who happen
to test positive using the current array of assays, are truly
infected. Therefore, there is an urgent need for a gold
standard, FDA-approved diagnostic test for HHV-8. The
difficulty in detecting HHV-8 in patients makes develop-
ment of a gold standard seroassay difficult at best and the
determination of specificity almost impossible. The cur-
rent, incomplete understanding of how HHV-8 is trans-
mitted, and the risk factors associated with its
transmission add to the burden of correlating diagnostic
test results to true infection. For example, a patient admit-
ted to an emergency room complaining of myalgia, fever,
and headaches could be presenting with symptoms from
any number of infectious or non-infectious illnesses.
However, if the clinical history indicates a recent walk in
the woods with a tick bite, then the diagnostic picture nar-
rows to include the possibility of ehrlichiosis or borrelio-
sis. The translation of research knowledge into the clinical
arena will require careful development, evaluation, opti-
mization, and refinement to develop a new standard of
care that blends advances in both diagnostic and clinical
sciences [287].
There are other deficiencies in HHV-8 diagnostic testing
methods. First, there is no effective HHV-8 confirmatory
assay similar to the Western blot used with HIV. Because
of the large variability of results between current tests and
between tested populations, it is difficult to find agree-
ment between two tests, except perhaps, in KS patients.
The inconsistent assay results also impede development
of effective diagnostic algorithms. Second, the availability
of an antigen capture assay (currently unavailable) would
benefit HHV-8 diagnostics in several ways. For example,
knowledge of the time course and concentrations of virus
circulating in patients (temporal antigenemia) could help
elucidate the natural history of HHV-8 infection, which in
turn could be utilized to detect early HHV-8 infection, to
confirm infection, and to monitor therapy. Suitable anti-
gens with high copy number such as capsid proteins
would be required. High affinity and high avidity anti-
bodies would need to be identified or developed, and
preferential access to the respective recombinant antigen
would be required for test development and for use as test
controls. Fortunately, commercial and research sources of
antibodies exist against both latent and lytic antigens,
Table 2: Companies or institutions that provide molecular testing services or research kits for the detection HHV-8 infection.
Molecular testing & kits
Company Test Utility
Focus Diagnostics, Inc. Herndon, VA, USA PCR, qualitative Method for identifying individuals among HIV+ 
persons who are at increased risk for 
developing KS. "The results are for research 
use only, and should not be used for diagnostic 
purposes."
ViraCor Laboratories Lee's Summit, MO, 
USA
Real-time PCR, quantitative (100 copies/ml to 1 
× 1010 copies/ml)
Clinical diagnostics: Determination of HHV-8 
primary infection and for determining the risk 
of developing KS among organ transplant 
patients and patients taking immune 
suppressive drugs.
ARUP Laboratories Salt Lake City, UT, USA Real-time PCR, qualitative (limit of detection: 1 
in 100,000 cells)
Clinical diagnostics: To predict the 
development of KS, to aid differential diagnosis 
in other vascular neoplasms and inflammatory 
conditions that are histologically similar to KS, 
to diagnose PELs, and to monitor patients with 
immune compromise or dysregulation.
LabPLUS Auckland City Hospital, New 
Zealand.
PCR, qualitative Clinical diagnostics: Diagnosis in KS, PEL, MCD
Medical Diagnostic Laboratories, L.L.C. 
Hamilton, NJ, USA
PCR, qualitative Clinical diagnostics
UT Southwestern Medical Center Dallas, 
TX, USA
Real-time PCR, qualitative Clinical diagnostics
Celonex Edmonton, Alberta, Canada Single HHV-8 ViruChip™ Gene expressionVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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such as LANA1, K8.1, Orf 65, and Orf 59, which will accel-
erate development of antigen assays.
There is a deficiency of HHV-8 antigenic proteins for use
in diagnostic tests. Current HHV-8 ELISAs target IgG anti-
bodies to one of three viral antigens: K8.1 [235], Orf 65
[59], or Orf 73 [235]. To date, no other useful HHV-8 pro-
teins have been discovered that provide acceptable sensi-
tivity and specificity in all populations tested, despite a
viral genome that can express over 47,000 amino acids.
Further research into identifying antigenic proteins is
needed.
The use of Western blot as a screening tool for HHV-8 is
impractical, and Western blot confirmatory tests suffer
from nonspecific reactions when whole cell lysates are
used. Currently, the choice of HHV-8 antigens is limited
for development of recombinant immunoblots making
the formulation of confirmatory Western blots difficult.
Although many published reports have confirmed the
utility of antibody isotype tests other than IgG for the
detection of other herpes viral infections, there is a dearth
of reports detecting anti-HHV-8 IgA and IgM antibody iso-
types. For example, patients with chronic fatigue syn-
drome and multiple sclerosis were more apt to have IgM
antibodies against HHV-6 [288,289]. IgA against EBV VCA
is at a higher seroprevalence and geometric mean titer in
patients with EBV-positive gastric carcinomas [290], and
is predictive of nasopharyngeal carcinoma [291]. This is in
contrast to HHV-8 where there are few reports of HHV-8
antibody isotype assays for IgA and IgM
[92,167,223,249,257,292], and none where the investiga-
tor compared IgG, IgA, and IgM isotypes concurrently in
the same laboratory with the same tests and serum sam-
ples. Theoretically, detection of IgA and IgM anti-HHV-8
might improve identification of HHV-8 infection and pro-
vide early diagnosis. IgA and IgM isotype detection could
also be incorporated into improved diagnostic algorithms
to better define the prevalence and disease associations of
HHV-8 infection.
If HHV-8 is similar to other herpesviruses, there may be
difficulty in identifying specific antigens to which the
majority of infected individuals have mounted an anti-
body response. For example, among the many other viral
structural proteins of HCMV, only one, pp150, is recog-
nized by most infected individuals [293] and a p101 pro-
tein was found to be most antigenic for HHV-6 [294].
Finding immunodominant antigens may take extended
study and application of novel techniques. In addition,
determining the sequence of specific antigenic gene prod-
ucts from viral isolates from diverse geographic regions is
necessary to ensure that antigens used as a lure for HHV-8
specific antibodies are universally detected [216,295].
In regards to molecular testing, only a few reports have
evaluated the utility and efficacy of performing PCR on
Table 3: Companies or institutions that provide serologic testing services or research kits for the detection HHV-8 infection.
Serologic testing & kits
Company Test Utility
Fred Hutchinson Cancer Research 
Center Seattle, WA, USA
ELISA Clinical diagnostics
Focus Diagnostics, Inc. Herndon, VA, USA IgG IFA Method for identifying individuals among HIV+ 
persons who are at increased risk for 
developing KS. "The results are for research 
use only, and should not be used for diagnostic 
purposes."
Quest Diagnostic (Focus Technologies) 
Baltimore, MD, USA
IgG IFA "This test should not be used for diagnosis 
without confirmation by other medically 
established means".
Advanced Biotechnologies Inc Columbia, 
MD, USA
1) IgG Antibody IFA Kit
2) IgG Antibody ELISA Kit (whole virus lysate)
For research use only.
Biotrin International The Rise, Mount 
Merrion Co. Dublin, Ireland
1)IgG IFA assay
2) DIAVIR HHV-8 peptide mix (Orf 65 & 
K8.1A) ELISA
For research use only. To aid in the diagnosis 
of primary infection or to identify reactivation 
or reinfection. To determine current or recent 
infection by testing of paired specimens of 
plasma or serum taken 7–14 days apart; a ≥ 4-
fold rise in titer is indicative of recent infection.
Panbio Inc. Columbia, MD, USA 1) IgG IFA (Lytic)
2) IgG IFA (Latent)
3) DIAVIR HHV-8 peptide mix (Orf 65 & 
K8.1A) ELISA
For research use onlyVirology Journal 2005, 2:78 http://www.virologyj.com/content/2/1/78
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activated PBMCs isolated from persons potentially
infected with HHV-8. Cell culture activation of a blood
donor's PBMCs using IL-2, TPA, and hIL-6 increased
detection from 1/7 to 5/7 serial samples [58]. Another
report showed that the presence of inflammatory
cytokines, specifically Inf-γ, increased the HHV-8 viral
load to detectable limits in cultured PBMCs derived from
both AIDS-KS and non-KS AIDS seropositive patients
[48]. Studies to confirm this seemingly useful approach
and to define the optimal viral amplification procedures
are needed.
The reverse transcriptase PCR (RT-PCR) assay is a popular
molecular diagnostic test for retroviruses or RNA viruses,
such as HCV or HGV. RT-PCR is usually not necessary for
DNA viruses, because the viral genomic DNA itself can be
detected without the intermediate step of reverse tran-
scriptase to create cDNA. However, since the unique latent
biology of HHV-8 renders DNA PCR of HHV-8 relatively
insensitive, RT-PCR should be studied more thoroughly as
an alternative diagnostic test for the detection of HHV-8
infection. The rationale is that detection of mRNA pro-
vides a built in preamplification step for detection of the
viral nucleic acid, because mRNA is at a higher copy
number than the corresponding genomic DNA. This
method could also allow the detection of both latent and/
or lytic transcripts increasing the chances of success. To
our knowledge, there are no reports in the literature that
RT-PCR has been evaluated seriously as a diagnostic or
screening assay for HHV-8 infection.
As an adjunct to the necessity of improved HHV-8 diag-
nostics, the effective use of HHV-8 viral therapy will
depend on the development of sensitive and specific
HHV-8 diagnostic tests to gauge the therapy's effective-
ness. Accumulating research either has implicated HHV-8
as the etiologic agent of diseases such as KS or has associ-
ated the virus indirectly with disease development. The
efficacy of clinical therapeutic drug interventions for
HHV-8 infection has not been studied thoroughly in clin-
ical settings, rather, mainly through in vitro experiments.
Prospective anti-HHV-8 therapeutic trials of anti-herpetic
drugs are needed in large and diverse cohorts of AIDS
patients presenting with KS. Organ transplant patients, in
order to prevent organ rejection, also require intense
study to determine the proper anti-HHV-8 intervention in
the absence of HAART and in the presence of immuno-
suppressive therapy. It will be more difficult to study the
therapy of patients with PEL and MCD because of the low
prevalence of these diseases.
Modern medicine will be able to manage this novel
human herpesvirus only through continued research into
the dynamics of HHV-8 infection in vivo, and the identi-
fication of important and unique antigens and their sub-
sequent development into diagnostics tests. Such
advances in turn will result in better understanding of the
pathogenesis and associated diseases of HHV-8 and cata-
lyze antiviral therapy and strategies for prevention.
10. Conclusion
Although the prevalence of HHV-8 is not as ubiquitous as
other human herpesviruses, there is strong evidence that it
is required and quite possibly is the primary etiological
agent for the formation of several life threatening neo-
plasms, including KS. Therefore, the development and
optimization of improved diagnostic assays is critical for
the identification, diagnosis, and monitoring of HHV-8
infection. Our work at the University of Maryland Balti-
more has addressed important issues in the field of HHV-
8 investigation; namely, the lack of a gold standard sero-
logic assay to detect the virus or antibodies to the virus, a
lack of optimization of current serologic assays, few relia-
ble diagnostic HHV-8 antigens available for serologic
tests, the epidemiology of HHV-8, and an incomplete
understanding of the host humoral response to HHV-8
infection.
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